

10/587844

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/035805

International filing date: 27 October 2004 (27.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/515,537
Filing date: 28 October 2003 (28.10.2003)

Date of receipt at the International Bureau: 13 December 2004 (13.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1257378

THE UNITED STATES OF AMERICA

BY AND BY WITNESS THESE PRESENTS, SEAL COMBED

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

December 07, 2004


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/515,537

FILING DATE: *October 28, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/35805*

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office

10/28/03
17178 US
60/515537
102803

Express Mail No. EV335857534US

COVER SHEET FOR PROVISIONAL APPLICATION FOR PATENT

Commissioner for Patents
P.O. Box 1450
Stop Provisional Patent Application
Alexandria, VA 22313-1450

22151 U.S.P.T.O.
60/515537

Sir:

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

<table border="1"><tr><td>Docket Number</td><td>11134-032-888</td><td>Type a plus sign (+) inside this box 6</td><td>+</td></tr></table>				Docket Number	11134-032-888	Type a plus sign (+) inside this box 6	+
Docket Number	11134-032-888	Type a plus sign (+) inside this box 6	+				
INVENTOR(s) APPLICANT(s)							
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)				
Goto Harada Imamura Kakutani	Hiroyuki Kazuhiro Katsuaki Makoto		Tokyo, Japan Tokyo, Japan Tokyo, Japan Tokyo, Japan				
TITLE OF THE INVENTION (280 characters max)							
TRIAZOLE COMPOUNDS HAVING HSD1 INHIBITORY ACTIVITY							
PENNIE & EDMONDS LLP CORRESPONDENCE ADDRESS :20583							
ENCLOSED APPLICATION PARTS (check all that apply)							
<input checked="" type="checkbox"/> Specification	Number of Pages	93	<input type="checkbox"/> Applicant claims small entity status, see 37 CFR §1.27				
<input type="checkbox"/> Drawing(s)	Number of Sheets		<input type="checkbox"/> Other (specify)				
METHOD OF PAYMENT (check one)							
<input type="checkbox"/> A check or money order is enclosed to cover the Provisional filing fees.			ESTIMATED PROVISIONAL FILING FEE AMOUNT <input checked="" type="checkbox"/> \$160 <input type="checkbox"/> \$80				
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge the required filing fee to Deposit Account Number 16-1150.							

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.
 No. Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

Signature By: *Anthony M. Insogna, Reg. No. 35,203*
Anthony M. Insogna
PENNIE & EDMONDS LLP
REGISTRATION NO.
(if appropriate)
51,463

35,203	Date	10/28/03
--------	------	----------

Additional inventors are being named on separately numbered sheets attached hereto.

Total number of cover sheet pages.

2

PROVISIONAL APPLICATION FILING ONLY

ADDITIONAL INVENTOR(s) APPLICANT(s)

LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)
Matsuda	Isamu		Tokyo, Japan
Ohe	Yasuhiro		Tokyo, Japan
Powers	Jay		Pacifica, California
Yata	Shinji	P.	Tokyo, Japan

TRIAZOLE COMPOUNDS HAVING HSD1 INHIBITORY ACTIVITY

TECHNICAL FIELD OF THE INVENTION

5 The present invention relates to triazole compounds having HSD1 inhibitory activity.

BACKGROUND OF THE INVENTION

11Beta-hydroxysteroid dehydrogenase 1 (hereinafter, "11beta-HSD1" or "HSD1") catalyzes the interconversion of glucocorticoids (hereinafter, "GC") between inert 11-keto forms (e.g. cortisone, 11-dehydrocorticosterone) and active 11beta-hydroxy forms (e.g. cortisol, corticosterone, respectively). The enzyme, *in vivo*, prefers the reductase direction from the 11-keto to the 11beta-hydroxy, in other words, the production of active GC.

11Beta-HSD1 is ubiquitously expressed, most notably in liver, lung, adipose tissue, vasculature, ovary and the central nervous system.

20 Until recently, experimental results have suggested that the active form of GC produced through HSD1 as well as the enzyme itself is involved in several biological actions and diseases.

25 For example, the active GC is known to stimulate gluconeogenic enzymes and have effects at least in part in inducing hyperglycemia. In this situation, HSD1 can be a second source of GC production in addition to the adrenal glands.

30 As another example, continuous excessiveness of the active GC in peripheral tissues, as observed in Cushing's syndrome, leads to insulin resistance, where HSD1 is considered to have an important role.

Also, in adipose tissue, active GC is demonstrated to enhance the differentiation of preadipocytes into adipocytes. Mature adipocytes express HSD1 activity, which causes an increase in local concentration of the active form and further 5 expansion of adipose tissue. Such an action of HSD1 should be critical in pathogenesis of obesity.

In addition, a local immunosuppressive effect of HSD1 in placental decidua, and a relationship between the expression of the enzyme in adrenal cortex and the induction 10 of adrenaline synthesis, are suggested.

(The above are referred to in: Quinkler M, Oelkers W & Diederich S (2001) European Journal of Endocrinology Vol. 144, Pages 87-97; and Seckl JR & Walker BR (2001) Endocrinology Vol. 142, Pages 1371-1376.)

15 According to the above suggestions, it is expected that drugs having inhibitory effects against HSD1 would be useful for treating or preventing diabetes mellitus, obesity, metabolic syndrome in connection with any of such diseases, or any other diseases which occur by reason of the actions of 20 HSD1.

Diabetes mellitus, main feature of which disease is chronic hyperglycemia, introduces various metabolic abnormalities and shows symptoms of thirst, polydipsia, polyuria, and so on based on high glucose concentration.

25 Continuing hyperglycemic state would also lead to diabetic complications such as retinopathy, nephropathy, neuropathy, and myocardial and/or cerebral infarction by reason of arteriosclerosis.

In treating diabetes, moderate suppression of 30 hyperglycemia is critical in order that onset and progress of the complications would be repressed. For these purposes, dietetics, ergotherapy and pharmacotherapy are utilized in

combination on a suitable basis and, amongst the pharmacotherapy, many approaches different in mechanisms of action have been attempted. In spite of those various existing methods, sufficient therapeutic effect has not ever been
5 achieved.


Obesity is defined as a state of fatness coinciding with any disease that would be improved or not be progressed in case of weight decrease (e.g. diabetes, hyperlipidemia, hypertension) or with an excessive amount of fat in viscera.

10 It is considered that, if such a state should continue, at least two of diabetes, hyperlipidemia, hypertension and etc. would concur, and then onset of myocardial and/or cerebral infarction by reason of arteriosclerosis would occur.

Major therapeutic methods in treating obesity are
15 dietetics and ergotherapy, and pharmacotherapy is undertaken only if necessary, for example, because of difficulty in the first two alternatives. However, the existing drugs have several problems in adverse effects and usages, since most of them suppress feeding mainly via central action.

20 In consequence, development of any drug to treat diabetes and/or obesity with a novel mechanism of action has so far been required. Under these circumstances, it is expected that drugs having inhibitory effects against HSD1 would be useful as another alternative with separate
25 mechanistic approach to treat diabetes mellitus, as well as a novel "adipose tissue-acting" class among other drugs against obesity.

As drugs in development to treat diabetes and/or obesity through inhibition of HSD1, for example, WO 03/065983
30 discloses triazole compounds of the following general formula:



[wherein:

R^1 is unsubstituted or substituted adamantyl;

W is $-N(R^a)-$ or single bond;

⁵ X is -CH₂- or single bond;

Z is -S- or single bond;

R^a is -H or C₁₋₆ alkyl unsubstituted or substituted with one to five fluorines;

R^2 is -H, unsubstituted or substituted C_{1-10} alkyl,

10 unsubstituted or substituted C₂₋₁₀ alkenyl, -CH₂CO₂H, -CH₂CO₂C₁₋₆ alkyl, -CH₂CONHR^a, -(CH₂)₀₋₂C₃₋₉ cycloalkyl (optionally having double bonds, and either

15 unsubstituted or substituted), $-(CH_2)_{0-2}$ adamantyl (either
unsubstituted or substituted) or $-(CH_2)_{0-2}R$:

R^3 is -H, unsubstituted or substituted C_{1-12} alkyl.

unsubstituted or substituted C₂₋₁₀ alkenyl, -YC₃₋₉

cycloalkyl (optionally having double bonds, and either

20 unsubstituted or substituted), -YC₅₋₁₂ bicycloalkyl

(optionally having double bonds, and either

R is benzodioxolane, furan, tetrahydrofuran, thiophene,

25 tetrahydrothiophene, dihydropyran, tetrahydropyran,

pyridine, piperidine, benzofuran, dihydrobenzofuran,

benzothiophene, dihydrobenzothiophene, indole,

dihydroindole, indene, indane, 1,3-dioxolane, 1,3-

dioxane, phenyl or naphthyl (any such R unsubstituted

substituted); and
Y is -(CH₂)₀₋₂₋ or (-HC=CH-).

However, any description under said application does not disclose nor refer to any of the compounds having the
5 structure of the present invention.


The compounds of the present invention improve physicochemical (stability, etc.) and biological (activity to inhibit HSD1, specificity, bioavailability, metabolism, etc.) profiles, as a result of the selection of structural
10 characteristics as disclosed herein.

SUMMARY OF THE INVENTION

According to the present invention, it has been found that triazole compounds represented by the following formula
15 have superior HSD1 inhibitory activity, and are useful as HSD1 inhibitors or therapeutic drugs of diabetes or obesity.

The present invention provides the following.

(1) A triazole compound represented by the following formula:



wherein

R¹ is an alkyl group or a cycloalkyl group
wherein the alkyl group and the cycloalkyl group are
optionally substituted by 1 to 5 substituents each
25 independently selected from a halogen atom, -CF₃, -OH,
-NH₂, an alkoxy group, a cycloalkyl group, an alkenyl
group, -COOH, -CO-O-alkyl, -CO-N(R⁷)(R⁸), -N(R⁷)-CO-R⁸, an
aryl group and a heteroaryl group
wherein R⁷ and R⁸ are each independently a hydrogen

atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, 5 $-(CH_2)_n-OH$, $-N(R^9)(R^{10})$, $-CN$, $-NO_2$, an alkoxy group, a cycloalkyl group, an alkenyl group, $-CO-R^{11}$, an aryl group and a heteroaryl group

wherein n is 0-3, R^9 and R^{10} are each independently a hydrogen atom, an alkyl group or $-CO$ -alkyl, and 10 R^{11} is $-OH$, an alkoxy group, an alkyl group or $-N(R^{12})(R^{13})$ wherein R^{12} and R^{13} are each independently a hydrogen atom or an alkyl group;

Y is a cycloalkyl group or a heterocycloalkyl group 15 wherein the cycloalkyl group and the heterocycloalkyl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, $-(CH_2)_n-OH$, $-N(R^9)(R^{10})$, $-CN$, $-NO_2$, an alkoxy group, a cycloalkyl group, an alkenyl group, $-CO-R^{11}$, an aryl group and a heteroaryl group (n, R^9 , R^{10} and R^{11} are as 20 defined above);

Ar^1 is an aryl group or a heteroaryl group;

R^2 and R^3

25 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, $-(CH_2)_n-OH$, $-N(R^9)(R^{10})$, $-CN$, $-NO_2$, an alkoxy group, a cycloalkyl group, an alkenyl group, $-CO-R^{11}$, an aryl group or a heteroaryl group

30 wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, $-(CH_2)_n-OH$,

-N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above);

5 Z is -(CH(R¹⁴))_p-, -(CH(R¹⁴))_p-N(R¹⁶)-(CH(R¹⁵))_q- or



wherein Y₁ is a cycloalkyl group or a heterocycloalkyl group

wherein the cycloalkyl group and the heterocycloalkyl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above),


10 p is 0-3, q is 0-3, R¹⁴ and R¹⁵ are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group or a heteroaryl group

15 wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and

20 25 30 R¹⁶ is a hydrogen atom, a haloalkyl group, an alkyl

group, $-(CH_2)_n-OH$, $-(CH_2)_n-CO-R^{11}$, a cycloalkyl group, an alkenyl group, an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, $-(CH_2)_n-OH$, $-N(R^9)(R^{10})$, $-CN$, $-NO_2$, an alkoxy group, a cycloalkyl group, an alkenyl group, $-CO-R^{11}$, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above);


Ar² is an aryl group, a heteroaryl group or



wherein X₁ is $-(CH_2)_t-$ wherein t is 0-2, V₁ is =CH- or =N-, and W₁ is $-C(R^{17})(R^{18})-$, $-O-$, $-S-$, $-SO_2-$, $-SO-$, $-CO-$ or $-N(R^{19})-$

wherein R¹⁷ and R¹⁸ are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, $-(CH_2)_r-OH$, $-CO-R^{20}$, $-N(R^{21})(R^{22})$ or $-L_1-Ar^3$ wherein r is 0-3, R²⁰ is -OH, an alkoxy group, an alkoxyalkyl group or $-N(R^{23})(R^{24})$

wherein R²³ and R²⁴ are each independently a hydrogen atom, an alkyl group, $-(CH_2)_s-OH$, an alkoxyalkyl group, or in combination form



wherein s is 0-3, X₂ is $-O-$, $-(CH_2)_t-$ or $-N(R^{25})-$ wherein t is as defined above and R²⁵ is a hydrogen atom, $-CO-R^{26}$, $-SO_2-R^{26}$ or $-(CH_2)_u-Ar^4$ wherein R²⁶ is an alkyl group, an alkoxy

group, -NH-alkyl or -N(-alkyl)₂, u is 0-3, and Ar⁴ is an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), L₁ is -(CH₂)_v-, -O- or -CO- wherein v is 0-3, and Ar³ is an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and R²¹ and R²² are each independently a hydrogen atom, an alkyl group, -CO-alkyl, -CO-O-alkyl or -L₁-Ar³ (L₁ and Ar³ are as defined above), and R¹⁹ is a hydrogen atom, -CO-R²⁶, -SO₂-R²⁶ or -(CH₂)_u-Ar⁴ (R²⁶, u and Ar⁴ are as defined above); and R⁴ and R⁵ are each independently a hydrogen atom, a halogen atom, -OH, -NO₂, -CN, an alkyl group, an alkoxy group, -CO-R²⁷, -SO₂-R²⁷, -CO-N(R²⁸)(R²⁹) or -N(R³⁰)(R³¹) wherein the alkyl group and the alkoxy group are optionally substituted by 1 to 5 substituents each

independently selected from a halogen atom, -CF₃, -OH, an alkoxy group, a haloalkoxy group, -N(R⁹)(R¹⁰), -CN, -NO₂, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (R⁹, R¹⁰ and R¹¹ are as defined above),

5

wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above)

10

R²⁷ is -OH, an alkoxy group, an alkyl group, -NH₂, -NH-alkyl or -N(-alkyl)₂,


15

R²⁸ and R²⁹ are each independently a hydrogen atom, an alkyl group or -(CH₂)_w-R³²,

wherein w is 0-3 and R³² is -OH, -CF₃, an alkoxy group, -CONH₂ or -N(R³³)(R³⁴)


20

wherein R³³ and R³⁴ are each independently a hydrogen atom, an alkyl group, -CO-alkyl, or in combination form



(X₂ is as defined above)

or R²⁸ and R²⁹ in combination form



25 wherein X₃ is -CO-, -CH₂- or -CH₂-CH₂-, X₄ is

-O-, -(CH₂)_t-, -N(R²⁵)- or


wherein Y₂ is cycloalkyl or heterocycloalkyl



5 and t and R²⁵ are as defined above, and R³⁵ and R³⁶ are each independently a hydrogen atom, a halogen atom, an alkyl group optionally substituted by -OH, -OH, -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R³⁷, -N(R³⁸)(R³⁹)

10 wherein R³⁷ is -OH, an alkoxy group, -NH₂,

15 -NH-alkyl, -N(-alkyl)₂ or (X₂ is as defined above)




20 wherein the alkyl group in -NH-alkyl and -N(-alkyl)₂ and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, -CF₃, -OH,

25 an alkoxy group, a haloalkoxy group, -N(R⁹)(R¹⁰), -CN, -NO₂, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (R⁹, R¹⁰ and R¹¹ are as defined above),

30 wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and

R^{38} and R^{39} are each independently a hydrogen atom, an alkyl group, $-CO$ -alkyl or $-CO-O$ -alkyl, and

5 R^{30} and R^{31} are each independently a hydrogen atom, an alkyl group optionally substituted by $-OH$, $-SO_2-$




R^{40} , $-(CH_2)_x-CO-R^{41}$ or

wherein x is 0-3, R^{40} is an alkyl group or $-NH_2$, R^{41} is a hydrogen atom, an alkyl group optionally substituted by $-OH$, $-OH$, an alkoxy group, an alkoxyalkyl group or $-(CH_2)_s-$

10 $N(R^{42})(R^{43})$

wherein s is as defined above and R^{42} and R^{43} are each independently a hydrogen atom, an alkyl group, $-OH$, an alkoxy group, or in combination form



15 $(X_3, X_4, R^{35} \text{ and } R^{36} \text{ are as defined above})$,

V_2 is $=CH-$ or $=N-$ and W_2 is $-C(R^{44})(R^{45})-$, $-O-$ or $-N(R^{46})-$

20 wherein R^{44} and R^{45} are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, $-(CH_2)_r-OH$, $-CO-R^{47}$ or $-N(R^{48})(R^{49})$


25 wherein r is as defined above, R^{47} is $-OH$, an alkoxy group, an alkoxyalkyl group, $-N(R^{50})(R^{51})$

wherein R^{50} and R^{51} are each independently a hydrogen atom, an alkyl group, $-(CH_2)_s-OH$ (s is as

defined above) or an alkoxyalkyl group,
and

5 R⁴⁸ and R⁴⁹ are each independently a
hydrogen atom, an alkyl group, -CO-alkyl
or -CO-O-alkyl, and

R⁴⁶ is a hydrogen atom, -CO-R⁵² or -SO₂-R⁵²
wherein R⁵² is an alkyl group, an alkoxy
group, -NH-alkyl or -N(-alkyl)₂, or
R³⁰ and R³¹ in combination form



10 (X₃, X₄, R³⁵ and R³⁶ are as defined above),

or

R⁴ and R⁵ in combination may form -O-alkylene-O-,
a prodrug thereof or a pharmaceutically acceptable salt
thereof.

15 (2) The triazole compound of (1) above, wherein Z is
-(CH(R¹⁴))_p- and p is 0, a prodrug thereof or a
pharmaceutically acceptable salt thereof.

(3) The triazole compound of (2) above, wherein Y is a C₃₋₈
cycloalkyl group, a prodrug thereof or a pharmaceutically
20 acceptable salt thereof.

(4) The triazole compound of (3) above, wherein Ar¹ is a phenyl
group, a prodrug thereof or a pharmaceutically acceptable salt
thereof.

(5) The triazole compound of (4) above, wherein R² and R³ are
25 each independently a halogen atom or a hydrogen atom, a
prodrug thereof or a pharmaceutically acceptable salt thereof.

(6) A pharmaceutical composition comprising the triazole
compound of any of (1) to (5) above, a prodrug thereof or a
pharmaceutically acceptable salt thereof, and a
30 pharmaceutically acceptable carrier.

(7) An HSD1 (11beta-hydroxysteroid dehydrogenase 1) inhibitor comprising the triazole compound of any of (1) to (5) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

5 (8) A therapeutic or prophylactic drug of diabetes, which comprises the triazole compound of any of (1) to (5) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

10 (9) A therapeutic or prophylactic drug of obesity, which comprises the triazole compound of any of (1) to (5) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

15 (10) A therapeutic or prophylactic drug of metabolic syndrome, which comprises the triazole compound of any of (1) to (5) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

20 (11) A method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of the triazole compound of any of (1) to (5) above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

25 (12) A method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of the triazole compound of any of (1) to (5) above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

30 (13) A method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of the triazole compound of any of (1) to (5) above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

(14) The method of (11) above, wherein a different therapeutic

drug of diabetes is used in combination.

(15) The method of (14) above, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an α -glucosidase inhibitor and an insulin sensitizer.

(16) The method of (15) above, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopypamide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

(17) The method of (12) above, wherein a different therapeutic drug of diabetes is used in combination.

(18) The method of (17) above, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an α -glucosidase inhibitor and an insulin sensitizer.

(19) The method of (18) above, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopypamide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

(20) The method of (13) above, wherein a different therapeutic drug of diabetes is used in combination.

(21) The method of (20) above, wherein the different

therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an α -glucosidase inhibitor and an 5 insulin sensitizer.

(22) The method of (21) above, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, gliclopyramide, acetohexamide, 10 glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

(23) The method of (11) above, wherein a different therapeutic drug of obesity is used in combination.

15 (24) The method of (23) above, wherein the different therapeutic drug of obesity is Mazindol.

(25) The method of (12) above, wherein a different therapeutic drug of obesity is used in combination.

(26) The method of (25) above, wherein the different 20 therapeutic drug of obesity is Mazindol.

(27) The method of (13) above, wherein a different therapeutic drug of obesity is used in combination.

(28) The method of (27) above, wherein the different therapeutic drug of obesity is Mazindol.

25

DETAILED DESCRIPTION OF THE INVENTION

Respective substituents and moieties used in the present specification are defined in the following.

The "alkyl group" means a straight chain or branched 30 chain alkyl group. Examples thereof include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl

group, isopentyl group, neopentyl group, tert-pentyl group, 1-ethylpropyl group, hexyl group and the like. It is preferably a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.

5 For R¹, preferred are methyl, ethyl, propyl, isopropyl, butyl and isobutyl, and particularly preferred are methyl and isopropyl.

The "cycloalkyl group" means a saturated cyclic alkyl group. Examples thereof include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group and the like. It is preferably a cycloalkyl group having 3 to 8, more preferably 3 to 6, carbon atoms.

For R¹, preferred is cyclopropyl.

When R¹ is alkyl, cycloalkyl group as a substituent on 15 alkyl is preferably cyclopropyl.

For Y, preferred are cyclopropyl, cyclobutyl and cyclopentyl, and particularly preferred is cyclopropyl.

For Y₁, preferred are cyclopropyl, cyclobutyl and cyclopentyl, and particularly preferred is cyclopropyl.

20 The "heterocycloalkyl group" means a saturated 5- to 7-membered heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Examples thereof include tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, 25 pyrazolidinyl group, imidazolidinyl group, oxazolidinyl group, thiazolidinyl group, tetrahydropyranyl group, dioxolanyl group, dioxanyl group, piperidinyl group, piperazinyl group, morpholinyl group and the like.

For Y, preferred is piperidinyl.

30 For Y₂, preferred is dioxolanyl.

The "alkenyl group" means a straight chain or branched chain alkenyl group. Examples thereof include vinyl group, 1-

propenyl group, allyl group, 1-methyl-2-propenyl group, 1-but enyl group, 2-but enyl group, 3-but enyl group, 1-pentenyl group, 2-pentenyl group, 1-hexenyl group, 2-hexenyl group and the like. It is preferably a straight chain or branched chain ⁵ alkenyl group having 2 to 6, more preferably 2 to 4, carbon atoms.

When R¹ is alkyl, alkenyl group as a substituent on alkyl is preferably vinyl.

The "aryl group" means an aromatic hydrocarbon group. ¹⁰ Examples thereof include phenyl group, naphthyl group, anthryl group and the like. It is preferably a phenyl group or naphthyl group.

For Ar¹, Ar², Ar³ and Ar⁴, preferred are phenyl and naphthyl, and particularly preferred is phenyl.

The "heteroaryl group" means a monocyclic or fused 5- to 14-membered aromatic heterocyclic group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Examples thereof include furyl group, thienyl group, pyrrolyl group, oxazolyl group, ¹⁵ isooxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzoxazolyl ²⁰ group, indolizinyl group, quinolyl group, isoquinolyl group, quinazolinyl group, cinnolinyl group, quinoxalinyl group, phthalazinyl group, acridinyl group, phenazinyl group, naphthyridinyl group and the like. It is preferably a monocyclic or fused 5- to 10-membered aromatic heterocyclic ²⁵ group containing 1 to 3 heteroatoms selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which includes furyl group, thienyl group, pyrrolyl group, ³⁰

oxazolyl group, isooxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group,

⁵ benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzoxazolyl group and the like.

For Ar¹, preferred are thienyl, pyrrolyl and pyridyl.

For Ar², preferred are thienyl, pyrrolyl, oxazolyl, isooxazolyl, thiazolyl, imidazolyl, pyrazolyl and pyridyl, and ¹⁰ particularly preferred are thienyl and pyridyl.

For Ar³ and Ar⁴, preferred is pyridyl.

The "halogen atom" means fluorine atom, chlorine atom, bromine atom or iodine atom. It is preferably fluorine atom or chlorine atom.

¹⁵ For R² and R³, preferred is fluorine atom. In this case, Ar¹ is particularly preferably phenyl, where only the 4-position of the phenyl is substituted by fluorine atom.

For R⁴ and R⁵, preferred is chlorine atom. In this case, Ar² is particularly preferably phenyl, where at least the ²⁰ 2-position of the phenyl is substituted by chlorine atom.

The "haloalkyl group" means a haloalkyl group wherein the above-defined "alkyl group" is substituted by the above-defined "halogen atom". Examples thereof include fluoromethyl group, difluoromethyl group, trifluoromethyl group, ²⁵ bromomethyl group, chloromethyl group, 1,2-dichloroethyl group, 2,2-dichloroethyl group, 2,2,2-trifluoroethyl group and the like. It is preferably a straight chain or branched chain haloalkyl group having 1 to 6, more preferably 1 to 4, carbon atoms, particularly preferably a trifluoromethyl group.

³⁰ The "alkoxy group" means a straight chain or branched chain alkoxy group. Examples thereof include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group,

isobutoxy group, tert-butoxy group, pentyloxy group, hexyloxy group and the like. It is preferably a straight chain or branched chain alkoxy group having 1 to 6, more preferably 1 to 4, carbon atoms.

5 For R^2 and R^3 , preferred is methoxy.

For R^4 and R^5 , preferred are methoxy, ethoxy and isopropoxy.

The "haloalkoxy group" means a haloalkoxy group wherein the above-defined "alkoxy group" is substituted by the above-
10 defined "halogen atom". Examples thereof include fluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, bromomethoxy group, chloromethoxy group, 1,2-dichloroethoxy group, 2,2-dichloroethoxy group, 2,2,2-trifluoroethoxy group and the like. It is preferably a straight chain or branched
15 chain haloalkoxy group having 1 to 6, more preferably 1 to 4, carbon atoms.

The "alkoxyalkyl group" means an alkoxyalkyl group wherein the above-defined "alkyl group" is substituted by the above-defined "alkoxy group". Examples thereof include
20 methoxymethyl group, ethoxymethyl group, propoxymethyl group, isopropoxymethyl group, butoxymethyl group, isobutoxymethyl group, tert-butoxymethyl group, 2-methoxyethyl group, pentyloxymethyl group, hexyloxymethyl group and the like. It is preferably an alkoxyalkyl group wherein the alkyl group is
25 a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms and the alkoxy group is a straight chain or branched chain alkoxy group having 1 to 6, more preferably 1 to 4, carbon atoms.

For R^{23} , R^{24} and R^{41} , preferred are methoxymethyl and 2-
30 methoxyethyl.

The "-CO-alkyl" means an alkylcarbonyl group having the above-defined "alkyl group" as the alkyl moiety. Examples

thereof include acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, pentanoyl group, hexanoyl group and the like. It is preferably an alkylcarbonyl group wherein the alkyl moiety is 5 a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.

For R^9 , R^{10} , R^{21} , R^{22} , R^{33} , R^{34} , R^{38} , R^{39} , R^{48} and R^{49} , particularly preferred are acetyl, propionyl, butyryl and isobutyryl.

10 The "-CO-O-alkyl" means an alkyloxycarbonyl group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include methyloxycarbonyl group, ethyloxycarbonyl group, propyloxycarbonyl group, isopropyloxycarbonyl group, butyloxycarbonyl group, 15 isobutyloxycarbonyl group, sec-butyloxycarbonyl group, tert-butyloxycarbonyl group, pentyloxycarbonyl group, isopentyloxycarbonyl group, neopentyloxycarbonyl group, tert-pentyloxycarbonyl group, 1-ethylpropyloxycarbonyl group, hexyloxycarbonyl group and the like. It is preferably an 20 alkylloxycarbonyl group wherein the "alkyl moiety" is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.

For R^{21} , R^{22} , R^{38} , R^{39} , R^{48} and R^{49} , particularly preferred are methyloxycarbonyl, ethyloxycarbonyl, 25 propyloxycarbonyl, isopropyloxycarbonyl and tert-butyloxycarbonyl.

The "-NH-alkyl" means an alkylamino group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include methylamino group, ethylamino group, 30 propylamino group, isopropylamino group, butylamino group, isobutylamino group, sec-butylamino group, tert-butylamino group, pentylamino group, isopentylamino group, tert-

pentylamino group, hexylamino group and the like. It is preferably an alkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.

5 For R^{26} , R^{27} , R^{32} and R^{52} , particularly preferred are methylamino, ethylamino, propylamino and isopropylamino.

The " $-N(-alkyl)_2$ " means a dialkylamino group having the above-defined "alkyl group" as the alkyl moiety. Examples thereof include dimethylamino group, diethylamino group, 10 dipropylamino group, diisopropylamino group, dibutylamino group, diisobutylamino group, di(sec-butyl)amino group, di(tert-butyl)amino group, dipentylamino group, diisopentylamino group, di(tert-pentyl)amino group, dihexylamino group, N-ethyl-N-methylamino group, N-methyl-N-15 propylamino group, N-ethyl-N-propylamino group and the like.

It is preferably a dialkylamino group wherein the alkyl moiety is a straight chain or branched chain alkyl group having 1 to 6, more preferably 1 to 4, carbon atoms.

For R^{26} , R^{27} , R^{32} and R^{52} , particularly preferred are 20 dimethylamino, diethylamino and N-ethyl-N-methylamino.

The "alkyl" moieties of the "alkylamino group" and "dialkylamino group" are optionally substituted by 1 to 5 substituents each independently selected from halogen atom, $-CF_3$, $-OH$, alkoxy group, haloalkoxy group, $-N(R^9)(R^{10})$ 25 $(R^9$ and R^{10} are each independently hydrogen atom, alkyl group or $-CO-alkyl$), $-CN$, $-NO_2$, cycloalkyl group, alkenyl group, $-CO-R^{11}$ (R^{11} is $-OH$, alkoxy group, alkyl group or $-N(R^{12})(R^{13})$ wherein R^{12} and R^{13} are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. Here, the 30 substituent "aryl group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from halogen atom, haloalkyl group, alkyl group, $-(CH_2)_n-OH$

(n=0 - 3), -N(R⁹)(R¹⁰) (R⁹ and R¹⁰ are independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO₂, alkoxy group, cycloalkyl group, alkenyl group, -CO-R¹¹ (R¹¹ is -OH, alkoxy group, alkyl group or -N(R¹²)(R¹³) wherein R¹² and R¹³ are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group.

The "aryl group" and the "heteroaryl group" for R², R³, R⁶, R¹⁴, R¹⁵, R¹⁶, Ar³ and Ar⁴ are optionally substituted by 1 to 3 substituents each independently selected from halogen atom, haloalkyl group, alkyl group, -(CH₂)_n-OH (n=0 - 3), -N(R⁹)(R¹⁰) (R⁹ and R¹⁰ are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO₂, alkoxy group, cycloalkyl group, alkenyl group, -CO-R¹¹ (R¹¹ is -OH, alkoxy group, alkyl group or -N(R¹²)(R¹³) wherein R¹² and R¹³ are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group.

The "cycloalkyl group" and the "heterocycloalkyl group" for Y and Y₁ are optionally substituted by 1 to 3 substituents each independently selected from halogen atom, haloalkyl group, alkyl group, -(CH₂)_n-OH (n=0 - 3), -N(R⁹)(R¹⁰) (R⁹ and R¹⁰ are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO₂, alkoxy group, cycloalkyl group, alkenyl group, -CO-R¹¹ (R¹¹ is -OH, alkoxy group, alkyl group or -N(R¹²)(R¹³) wherein R¹² and R¹³ are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group.

The "alkyl group" and the "alkoxy group" for R⁴ and R⁵, and the "alkoxy group" for R³⁷ are optionally substituted by 1 to 5 substituents each independently selected from halogen atom, -CF₃, -OH, alkoxy group, haloalkoxy group, -N(R⁹)(R¹⁰) (R⁹ and R¹⁰ are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -NO₂, cycloalkyl group, alkenyl group, -CO-R¹¹ (R¹¹ is -OH, alkoxy group, alkyl group or -N(R¹²)(R¹³) wherein

R^{12} and R^{13} are each independently hydrogen atom or alkyl group, aryl group and heteroaryl group. Here, the substituent "aryl group" and "heteroaryl group" are optionally substituted by 1 to 3 substituents each independently selected from.

⁵ halogen atom, haloalkyl group, alkyl group, $-(CH_2)_n-OH$ ($n=0 - 3$), $-N(R^9)(R^{10})$ (R^9 and R^{10} are independently hydrogen atom, alkyl group or $-CO$ -alkyl), $-CN$, $-NO_2$, alkoxy group, cycloalkyl group, alkenyl group, $-CO-R^{11}$ (R^{11} is $-OH$, alkoxy group, alkyl group or $-N(R^{12})(R^{13})$ wherein R^{12} and R^{13} are each independently

¹⁰ hydrogen atom or alkyl group), aryl group and heteroaryl group.

The above-mentioned substituents "halogen atom", "haloalkyl group", "alkyl group", "alkoxy group", "haloalkoxy group", "cycloalkyl group", "alkenyl group", "aryl group" and

¹⁵ "heteroaryl group" are as defined above.

R^4 and R^5 in combination may form $-O$ -alkylene- O -. Here, the "alkylene" means a divalent hydrocarbon. Examples thereof include methylene, ethylene, propylene, butylene, pentylene, hexylene and the like. It is preferably an alkylene having 1

²⁰ to 6, more preferably 1 to 4, carbon atoms, particularly preferably methylene.

In the above-mentioned formulas, Z is preferably $-(CH(R^{14}))_p-$ and p is 0; Y is preferably a C_{3-8} cycloalkyl group; Ar^1 is preferably a phenyl group; R^2 and R^3 are

²⁵ preferably independently a halogen atom or a hydrogen atom.

The "pharmaceutically acceptable salt" may be any salt as long as it forms a non-toxic salt with a triazole compound represented by the above-mentioned formula. For example, it can be obtained by reaction with inorganic acids such as

³⁰ hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; organic acids such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid,

succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzenesulfonic acid and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide,
5 magnesium hydroxide, ammonium hydroxide and the like; organic bases such as methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, cinchonine, N-methyl-D-glucamine and the like; or amino acids
10 such as lysin, histidine, arginine, alanine and the like. In the present invention, a water-containing form, a hydrate and a solvate of each compound are also encompassed therein.

In addition, the triazole compound represented by the above-mentioned formula includes various isomers. For example,
15 E form and Z form are present as geometric isomers, and when an asymmetric carbon atom is present, enantiomers and diastereomers are present as stereoisomers based thereon. In some cases, a tautomer may be present. Accordingly, the present invention encompasses all these isomers and mixtures
20 thereof.

The present invention also encompasses prodrugs and metabolites of the triazole compound represented by the formula. A "prodrug" is a derivative of the compound of the present invention, which has a chemically or metabolically
25 decomposable group, which, after being administered to a living organism, restores to its original compound form and exhibit its intrinsic efficacy, and which includes complexes and salts free of a covalent bond. For example, ester derivatives known as prodrugs in the field of pharmaceutical
30 agents can be used.

When the compound of the present invention is used as a pharmaceutical preparation, it is generally admixed with a

pharmaceutically acceptable carrier, excipient, diluent, extender, disintegrant, stabilizer, preservative, buffer, emulsifier, fragrance, coloring agent, sweetening agent, thickening agent, corrigent, dissolution aids and other

5 additives known *per se*, such as water, vegetable oil, alcohols such as ethanol, benzyl alcohol and the like, polyethylene glycol, glycerol triacetate, gelatin, lactose, carbohydrates such as starch and the like, magnesium stearate, talc, lanolin, vaseline and the like, and produced in the form of
10 tablet, pill, powder, granule, suppository, injection, eye drop, liquid, capsule, troche, aerosol, elixir, suspension, emulsion, syrup and the like by a conventional method for systemic or local, oral or parenteral administration.

While the dose of the compound of the present invention
15 varies depending on the age, body weight, symptom, disease to be treated, administration method and the like, it is generally 50 mg to 800 mg for an adult per administration, which is given once to several times a day.

The compound of the present invention can be
20 administered to a mammal (human, mouse, rat, rabbit, dog, cat, bovine, pig, monkey etc.) as an HSD1 inhibitor, a prophylactic or therapeutic drug of diabetes, a prophylactic or therapeutic drug of diabetic complication (retinopathy, nephropathy, neuropathy, cardiac infarction and cerebral infarction based
25 on arteriosclerosis etc.), a prophylactic or therapeutic drug of hyperlipemia, a prophylactic or therapeutic drug of obesity, neurodegenerative disease and the like, or a prophylactic or therapeutic drug of diseases mediated by HSD1.

The compound of the present invention can be
30 administered to a mammal concurrently with other therapeutic drug of diabetes or obesity with the aim of the prophylaxis or treatment of diabetes. In the present invention, the

"therapeutic drug of diabetes" encompasses therapeutic drugs of diabetic complications. Furthermore, the compound of the present invention can be administered in combination with other therapeutic drugs of diabetes or obesity to a mammal for 5 the prophylaxis or treatment of obesity.

In the case of a combined administration, the compound of the present invention may be administered simultaneously with other therapeutic drugs of diabetes or other therapeutic drugs of obesity (hereinafter to be referred to as a combined 10 pharmaceutical agent) or may be administered at time intervals. In the case of a combined administration, a pharmaceutical composition containing the compound of the present invention and a combined pharmaceutical agent can be administered. Alternatively, a pharmaceutical composition 15 containing the compound of the present invention and a pharmaceutical composition containing a combined pharmaceutical agent may be administered separately. The administration routes of respective pharmaceutical compositions may be the same or different.

20 In the case of a combined administration, the compound of the present invention may be administered at a dose of 50 mg to 800 mg per administration, which is given once to several times a day. In addition, the compound may be administered at a smaller dose. The combined pharmaceutical 25 agent can be administered at a dose generally employed for the prophylaxis or treatment of diabetes or obesity or at a smaller dose than that.

As other therapeutic drug of diabetes to be used for the combined administration, insulin preparation, 30 sulfonylurea, insulin secretagogue, sulfonamide, biguanide, α -glucosidase inhibitor, insulin sensitizer and the like can be mentioned. For example, insulin, glibenclamide, tolbutamide,

glycipyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose, pioglitazone hydrochloride and the like can be used for combined




5 administration with the compound of the present invention.

As other therapeutic drug of obesity to be used for the combined administration, for example, mazindol can be mentioned.

Now one example of the production method of the triazole compound of the present invention is described in the following, which does not limit the production method of the compound of the present invention. Even in the absence of

15 description in the production method, efficient production can be afforded by introducing, where necessary, a protecting group into a functional group followed by deprotection in a subsequent step, exchanging the order of respective production methods and steps, and the like. The post-reaction treatment
20 can be applied by a typical method by selecting or combining conventional methods as necessary, such as isolation and purification, crystallization, recrystallization, silica gel chromatography, preparative HPLC and the like.

25 **Production Method 1:** In this production method, a triazole compound, wherein the atom linked to the 2- or 5-position (where the substituent Z is linked) of the triazole ring is carbon, is produced, and the method includes any of the following steps.



wherein each symbol is as defined above, provided that the atom linked to the 2- or 5-position (where the substituent Z is linked) of the triazole ring of the triazole compound to be formed is carbon.

Acylhydrazide (1) synthesized by a known method and thioimide (2) synthesized by a known method are reacted in a solvent to give triazole (3). As the solvent, methanol,



ethanol, n-propanol, n-butanol, isopropanol, acetonitrile,
diethyl ether, tetrahydrofuran (THF), 1,4-dioxane, N,N-
dimethylformamide, dimethyl sulfoxide, dichloromethane, 1,2-
dichloroethane, chloroform, benzene, chlorobenzene, o-
5 dichlorobenzene, toluene, xylene, pyridine, 2,6-lutidine,
2,4,6-collidine, acetic acid, water, or a mixed solvent
thereof can be mentioned. The reaction temperature is
preferably 20°C - 250°C.

When acylhydrazide (1) or thioimidate (2) is a salt,
10 the reaction is carried out in the presence of a base such as
sodium hydroxide, potassium hydroxide, lithium hydroxide,
sodium carbonate, potassium carbonate, sodium bicarbonate,
potassium bicarbonate, sodium acetate, potassium acetate,
sodium hydride, potassium hydride, triethylamine, N,N-
15 diisopropylethylamine, pyridine and the like.

Alternatively, triazole (3) can be obtained according
to a similar method from thioimidate (4) synthesized by a
known method and acylhydrazide (5) synthesized by a known
method.

20

Production Method 2: In this production method, a triazole
compound, wherein the atom linked to the 2- or 5-position
(where the substituent Z is linked) of the triazole ring is
nitrogen, is produced, and the method includes the following
25 steps.



7

wherein each symbol is as defined above, provided that the atom linked to the 2- or 5-position (where the substituent Z is linked) of the triazole ring of the triazole compound to be formed is nitrogen.

Triazole (7) can be obtained by reacting isothiourea (6) synthesized by a known method with acylhydrazide (5) synthesized by a known method in a solvent. As the solvent, methanol, ethanol, n-propanol, n-butanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran (THF), 1,4-dioxane, N,N-dimethylformamide, dimethyl sulfoxide, dichloromethane, 1,2-dichloroethane, chloroform, benzene, chlorobenzene, o-dichlorobenzene, toluene, xylene, pyridine, 2,6-lutidine, 2,4,6-collidine, acetic acid, water, or a mixed solvent thereof can be mentioned. The reaction temperature is preferably 20°C - 250°C.

When isothiourea (6) or acylhydrazide (5) is a salt, the reaction is carried out in the presence of a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate,

potassium bicarbonate, sodium acetate, potassium acetate, sodium hydride, potassium hydride, triethylamine, N,N-diisopropylethylamine, pyridine and the like.

The production methods described in this specification
5 are examples of the production methods of the compounds of the present invention, and compounds other than the compounds explained above can be produced by combining conventional methods known in the field of organic synthetic chemistry.


10

Examples

The triazole compound represented by the formula of the present invention and the production method thereof are explained in detail in the following by referring to Examples, which are not to be construed as limitative.

15

Example 1-1: Production of 3',5'-dichloro-4-(5-(1-(4-chlorophenyl)cyclopropyl)-4-methyl-4H-[1,2,4]triazol-3-yl)-3,4,5,6-tetrahydro-2H-[1,4']bipyridyl hydrochloride




20

Methyl 3',5'-dichloro-N-methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-imidethiocarboxylate hydroiodide (452 mg) and 1-(4-chlorophenyl)-cyclopropane carbohydrazide (178 mg)

were suspended in 1,4-dioxane (1.8 ml) and water (0.4 ml), sodium acetate (83 mg) was added and the mixture was heated under reflux overnight. The reaction solution was concentrated and extracted with ethyl acetate. The ethyl acetate layer was 5 washed successively with saturated aqueous sodium hydrogencarbonate solution, water and saturated brine, dried over anhydrous sodium sulfate and concentrated to dryness. The obtained residue was purified by silica gel chromatography (chloroform:acetone=1:1). Thereto was added 4N solution of 10 hydrogen chloride in ethyl acetate (0.16 ml) and the mixture was concentrated to dryness to give the title compound (203 mg).

¹H-NMR (400MHz, DMSO-d₆) δ 1.53-1.69 (4H, m), 1.91-2.08 (4H, m); 3.34-3.62 (5H, m), 3.62 (3H, s), 7.22 (2H, d, J=6.0Hz), 15 7.38-7.41 (2H, m), 8.47 (2H, s).

Example 2-1: Production of 1-[4-methyl-5-(1-phenylcyclopropyl)-4H-[1,2,4]triazol-3-yl]-4-phenylpiperidine



Methyl N-methyl-4-phenylpiperidine-1-imidethiocarboxylate hydroiodide (452 mg) and 1-phenylcyclopropane carbohydrazide (176 mg) were suspended in 1,4-dioxane (2 ml) and water (0.4 ml), sodium acetate (98 mg)
5 was added and the mixture was heated under reflux overnight. The reaction solution was concentrated and extracted with ethyl acetate. The ethyl acetate layer was washed successively with saturated aqueous sodium hydrogencarbonate solution, water and saturated brine, dried over anhydrous sodium sulfate
10 and concentrated to dryness. The obtained residue was purified by silica gel chromatography (chloroform:acetone=1:1). Thereto was added 4N solution of hydrogen chloride in ethyl acetate (0.25 ml) and the mixture was concentrated to dryness. Acetone was added and insoluble solids were collected by filtration
15 and dried to give the title compound (117 mg).
 $^1\text{H-NMR}$ (300MHz, DMSO- d_6) δ 1.50-1.66 (4H, m), 1.76-1.91 (4H, m), 2.70-2.80 (1H, m), 3.19-3.28 (2H, m), 3.43 (3H, s), 3.77 (2H, d, $J=12.8$ Hz), 7.20-7.39 (10H, m).

20 Examples 1-2 to 1-148:

In the same manner as in Example 1-1, and using other conventional methods as necessary, a triazole compound was produced. The structural formula and property values of each Example compounds are shown in the following Table.

25

Examples 2-2 to 2-99:

In the same manner as in Example 2-1, and using other conventional methods as necessary, a triazole compound was produced. The structural formula and property values of each
30 Example compounds are shown in the following Table.

Examples	Molecular Structure	$^1\text{H-NMR}$
----------	---------------------	------------------

Ex.1-1		(400MHz, DMSO-D6), 1.53-1.69 (4H, m), 1.91-2.08 (4H, m), 3.34-3.62 (5H, m), 3.62 (3H, s), 7.22 (2H, d, J=6.0Hz), 7.38-7.41 (2H, m), 8.47 (2H, s)
Ex.1-2		400MHz, DMSO-d6, 1.72-1.82 (4H, m), 1.93-2.12 (4H, m), 2.30-2.39 (2H, m), 2.47-2.58 (2H, m), 2.87-2.98 (2H, m), 3.26-3.38 (4H, m), 3.80-3.87 (2H, m), 6.99-7.04 (1H, m), 7.21-7.26 (2H, m), 7.29-7.42 (3H, m), 7.81-7.86 (1H, m), 8.20-8.23 (1H, m)
Ex.1-3		400MHz, DMSO-d6, 1.51-1.69 (4H, m), 1.95-2.14 (4H, m), 2.94-3.06 (2H, m), 3.31-3.40 (3H, m), 3.56 (3H, s), 7.15-7.36 (5H, m), 9.14-9.37 (2H, br)
Ex.1-4		300MHz, DMSO-d6, 1.50-1.77 (5H, m), 1.93-2.05 (4H, m), 2.63-2.73 (1H, m), 3.12-3.20 (1H, m), 3.27-3.33 (1H, m), 3.58 (3H, m), 3.89-3.96 (1H, m), 4.40-4.47 (1H, m), 7.13-7.37 (5H, m)
Ex.1-5		(DMSO-D6) 1.51-1.78 (4H, m), 1.88-2.14 (4H, m), 3.28-3.54 (7H, m), 4.14 (2H, t, J=5.5Hz), 7.22-7.42 (5H, m), 8.47 (2H, s)
Ex.1-6		(DMSO-D6) 1.51-1.79 (4H, m), 1.92-2.16 (4H, m), 2.27-2.90 (2H, m), 3.36-3.65 (5H, m), 4.32-4.48 (2H, m), 7.22-7.42 (5H, m), 8.40-8.61 (4H, m)
Ex.1-7		(DMSO-D6) 1.30-1.40 (2H, m), 1.50-1.58 (2H, m), 1.77 (3H, s), 1.82-2.01 (4H, m), 2.92-3.13 (3H, m), 3.26-3.48 (4H, m), 3.69-3.80 (2H, m), 7.04-7.37 (5H, m), 7.98-8.07 (1H, m), 8.43 (2H, s)
Ex.1-8		(CDCl3) 1.40-1.47 (2H, m), 1.60-1.65 (2H, m), 1.84-1.97 (2H, m), 2.18-2.36 (4H, m), 2.77-2.84 (1H, m), 3.32-3.56 (4H, m), 3.65 (3H, s), 3.98-4.08 (2H, m), 7.20-7.32 (5H, m), 8.32 (2H, s)

Ex.1-9		(DMSO-D6) 1.33-1.57 (4H, m), 1.81-2.02 (4H, m), 2.26 (2H, t, J=7.8Hz), 2.98-3.10 (1H, m), 3.20-3.43 (4H, m), 3.95 (2H, t, J=7.8Hz), 7.04-7.37 (5H, m), 8.44 (2H, s)
Ex.1-10		(DMSO-D6) 1.33-1.53 (4H, m), 1.82-2.02 (4H, m), 2.26 (2H, t, J=8.1Hz), 2.54 (3H, d, J=4.4Hz), 2.95-3.05 (1H, m), 3.28-3.44 (4H, m), 3.97 (2H, t, J=8.1Hz), 7.04-7.32 (5H, m), 7.77-7.83 (1H, m), 8.43 (2H, s)
Ex.1-11		(DMSO-D6) 1.36-1.47 (4H, m), 1.50-1.61 (2H, m), 1.62-1.80 (2H, m), 1.94-2.03 (2H, m), 2.10-2.20 (2H, m), 2.78-2.89 (1H, m), 3.39 (3H, s), 4.44-4.57 (1H, m), 6.97-7.03 (2H, m), 7.16-7.40 (5H, m), 7.52-7.59 (1H, m)
Ex.1-12		400MHz, DMSO-d6, 1.50-1.69 (4H, m), 2.08-2.37 (4H, m), 3.11-3.38 (4H, m), 3.46-3.57 (4H, m), 4.44 (2H, s), 7.15-7.37 (5H, m), 7.57-7.62 (1H, m), 7.77-7.81 (1H, m), 8.01-8.07 (1H, m), 11.6 (1H, brs)
Ex.1-13		400MHz, DMSO-d6, 1.64-1.76 (4H, m), 1.83-1.93 (4H, m), 2.12-2.23 (2H, m), 2.42-2.55 (2H, m), 2.90-2.99 (1H, m), 3.08 (3H, s), 3.25-3.46 (4H, m), 7.08-7.15 (2H, m), 7.19-7.26 (1H, m), 7.28-7.36 (2H, m), 8.43 (2H, s)
Ex.1-14		400MHz, DMSO-d6, 1.54-1.76 (4H, m), 1.88-2.16 (5H, m), 2.89-3.03 (2H, m), 3.26-3.41 (1H, m), 3.64 (3H, s), 3.77-3.91 (2H, m), 6.98-7.05 (1H, m), 7.16-7.41 (5H, m), 7.80-7.89 (1H, m), 8.20-8.27 (1H, m)
Ex.1-15		400MHz, DMSO-d6, 1.50-1.72 (4H, m), 1.86-2.12 (5H, m), 3.27-3.49 (4H, m), 3.62 (3H, s), 7.14-7.39 (5H, m), 8.47 (2H, s)
Ex.1-16		(400MHz, DMSO-D6), 1.91-2.05 (4H, m), 2.42-2.54 (2H, m), 2.62-2.72 (2H, m), 3.07-3.31 (4H, m), 3.23 (3H, s), 3.32-3.46 (5H, m), 7.20-7.54 (5H, m), 8.47 (2H, s), 9.15-9.37 (2H, m)

Ex.1-17		(400MHz, DMSO-D6), 1.94-2.07 (4H, m), 2.02 (3H, s), 2.09-2.30 (2H, m), 2.44-2.53 (2H, m), 3.30 (3H, s), 3.31-3.52 (5H, m), 4.06-4.14 (4H, m), 7.23-7.48 (5H, m), 8.48 (2H, s)
Ex.1-18		(300MHz, DMSO-D6), 1.50-1.70 (4H, m), 3.29 (3H, s), 7.09-7.17 (2H, m), 7.22-7.29 (1H, m), 7.31-7.38 (2H, m), 7.65 (2H, m), 7.91-7.95 (1H, m)
Ex.1-19		(300MHz, DMSO-D6), 1.44-1.64 (4H, m), 3.27 (3H, s), 7.17 (2H, s), 7.19 (2H, s), 7.66 (2H, m), 7.91 (1H, m)
Ex.1-20		(300MHz, CDCl3), 1.49-1.53 (2H, m), 1.67-1.71 (2H, m), 3.27 (3H, s), 7.15-7.18 (2H, m), 7.21-7.26 (1H, m), 7.30-7.35 (2H, m), 7.77 (1H, d, J=8.4Hz), 8.26 (1H, dd, J=2.3, 8.4Hz), 8.38 (1H, d, J=2.3Hz)
Ex.1-21		(300MHz, DMSO-D6), 1.53-1.57 (2H, m), 1.65-1.69 (2H, m), 2.11 (3H, s), 3.30 (3H, s), 7.13-7.15 (2H, m), 7.24-7.29 (1H, m), 7.33-7.38 (2H, m), 7.58 (1H, d, J=8.4Hz), 7.68 (1H, dd, J=2.2, 8.4Hz), 8.06 (1H, d, J=2.2Hz)
Ex.1-22		(300MHz, DMSO-D6) 1.44-1.57 (4H, m), 3.15 (3H, s), 3.19 (3H, s), 7.03-7.07 (2H, m), 7.19-7.35 (4H, m), 7.40 (1H, d, J=2.1Hz), 7.54 (1H, d, J=8.4Hz), 10.35 (1H, s)
Ex.1-23		(300MHz, DMSO-D6) 1.44-1.57 (4H, m), 3.19 (3H, s), 4.04 (2H, s), 5.75 (1H, brs), 7.05 (2H, d, J=7.8Hz), 7.19-7.35 (3H, m), 7.51 (1H, d, J=8.7Hz), 7.82 (1H, dd, J=1.8, 8.9Hz), 8.13 (1H, d, J=1.8Hz), 10.12 (1H, s)
Ex.1-24		(300MHz, DMSO-D6) 1.44-1.57 (4H, m), 3.19 (3H, s), 3.39 (3H, s), 4.06 (2H, s), 7.05 (2H, d, J=7.2Hz), 7.19-7.35 (3H, m), 7.52 (1H, d, J=8.4Hz), 7.77 (1H, dd, J=1.8, 8.4Hz), 8.08 (1H, d, J=1.8Hz), 10.19 (1H, s)

		7.76 (1H, dd, $J=2.1, 8.7\text{Hz}$) , 8.09 (1H, d, $J=2.1\text{Hz}$) , 11.74 (1H, s)
Ex. 1-32		(300MHz, DMSO-D6) 1.15-1.30 (2H, m) , 1.41 (9H, s) , 1.42-1.55 (4H, m) , 1.87-1.91 (2H, m) , 2.93 (2H, m) , 3.16 (3H, s) , 3.49 (1H, m) , 3.85-3.90 (2H, m) , 6.29 (1H, d, $J=8.1\text{Hz}$) , 6.66 (1H, dd, $J=2.1, 8.4\text{Hz}$) , 6.77 (1H, d, $J=2.1\text{Hz}$) , 7.02-7.05 (2H, m) , 7.17-7.34 (4H, m)
Ex. 1-33		(300MHz, DMSO-D6) 1.40-1.60 (4H, m) , 2.95 (6H, s) , 3.18 (3H, s) , 7.05 (2H, d, $J=7.5\text{Hz}$) , 7.19-7.35 (3H, m) , 7.40 (1H, d, $J=8.4\text{Hz}$) , 7.60 (1H, dd, $J=1.8, 8.4\text{Hz}$) , 7.88 (1H, d, $J=1.8\text{Hz}$) , 8.69 (1H, s)
Ex. 1-34		(300MHz, DMSO-D6) 1.53-1.71 (4H, m) , 3.32 (3H, s) , 7.12-7.59 (10H, m) , 10.31 (1H, s)
Ex. 1-35		(300MHz, DMSO-D6) 1.40-1.60 (4H, m) , 3.18 (3H, s) , 6.09 (2H, br. s) , 7.03-7.06 (2H, m) , 7.19-7.41 (5H, m) , 7.89 (1H, br. s) , 9.02 (1H, br. s)
Ex. 1-36		(300MHz, DMSO-D6) 1.44-1.58 (4H, m) , 3.19 (3H, s) , 4.10-4.16 (2H, m) , 4.46-4.51 (2H, m) , 7.06 (2H, m) , 7.19-7.35 (3H, m) , 7.60 (1H, d, $J=8.4\text{Hz}$) , 7.67 (1H, dd, $J=2.1, 8.4\text{Hz}$) , 7.92 (1H, d, $J=2.1\text{Hz}$)
Ex. 1-37		(300MHz, DMSO-D6) 1.41-1.55 (4H, m) , 3.12-3.18 (2H, m) , 3.16 (3H, s) , 3.53-3.59 (2H, m) , 4.74 (1H, t, $J=5.4\text{Hz}$) , 6.36 (1H, t, $J=5.7\text{Hz}$) , 6.66 (1H, dd, $J=2.1, 8.7\text{Hz}$) , 6.76 (1H, d, $J=2.1\text{Hz}$) , 7.03 (2H, d, $J=7.5\text{Hz}$) , 7.17-7.34 (4H, m)
Ex. 1-38		(300MHz, DMSO-D6) 1.26 (3H, t, $J=6.9\text{Hz}$) , 1.43-1.57 (4H, m) , 3.18 (3H, s) , 4.17 (2H, q, $J=6.9\text{Hz}$) , 7.05 (2H, m) , 7.19-7.34 (3H, m) , 7.47 (1H, d, $J=8.4\text{Hz}$) , 7.54 (1H, dd, $J=1.8, 8.4\text{Hz}$) , 7.89 (1H, d, $J=1.8\text{Hz}$) , 10.09 (1H, s)

Ex. 1-39		(300MHz, DMSO-D6) 1.43-1.58 (4H, m), 3.18 (3H, s), 3.41-3.47 (2H, m), 3.88-3.94 (2H, m), 7.06 (2H, m), 7.19-7.35 (4H, m), 7.49 (1H, d, J=8.4Hz), 7.58 (1H, dd, J=2.4, 8.4Hz), 7.97 (1H, d, J=2.4Hz)
Ex. 1-40		(300MHz, DMSO-D6) 1.40-1.57 (6H, m), 1.83-1.90 (2H, m), 3.13-3.21 (5H, m), 3.27 (3H, s), 3.40 (1H, m), 3.74-3.79 (2H, m), 7.05 (2H, m), 7.19-7.35 (3H, m), 7.40 (1H, d, J=8.4Hz), 7.57 (1H, dd, J=1.8, 8.4Hz), 7.86 (1H, d, J=1.8Hz), 8.92 (1H, s)
Ex. 1-41		(300MHz, DMSO-D6) 1.35-1.57 (6H, m), 1. 70 (1H, m), 1.87 (1H, m), 2. 2.81 (1H, dd, J=8.4, 12.9Hz), 3. 2.99 (1H, m), 3.18 (3H, s), 3.48 (1H, m), 4. 3.74 (1H, m), 3.91 (1H, m), 5. 3.85 (1H, d, J=4.2Hz), 7.05 (2H, m), 6. 7.19-7.35 (3H, m), 7. 7.40 (1H, d, J=8.4Hz), 8. 7.57 (1H, dd, J=2.1, 8.4Hz), 9. 7.86 (1H, d, J=2.1Hz), 8.87 (1H, s)
Ex. 1-42		(300MHz, DMSO-D6) 1.32-1.57 (6H, m), 1.65-1.80 (2H, m), 3.10-3.18 (2H, m), 3.68 (1H, m), 3.80-3.85 (2H, m), 4.27 (1H, d, J=4.5Hz), 7.05 (2H, m), 7.19-7.35 (3H, m), 7.40 (1H, d, J=8.7Hz), 7.56 (1H, dd, J=2.1, 8.4Hz), 7.87 (1H, d, J=1.8Hz), 8.92 (1H, s)
Ex. 1-43		(300MHz, DMSO-D6) 1.46-1.55 (6H, m), 1.72-1.80 (2H, m), 2.21-2.28 (2H, m), 2.72-2.76 (2H, m), 3.13 (2H, s), 3.19 (3H, s), 3.49 (1H, m), 4.56 (1H, d, J=4.2Hz), 7.05 (2H, d, J=7.5Hz), 7.19-7.35 (3H, m), 7.50 (1H, d, J=8.4Hz), 7.74 (1H, d, J=1.8, 8.4Hz), 8.07 (1H, d, J=1.5Hz), 10.07 (1H, s)
Ex. 1-44		(300MHz, DMSO-D6) 1.17-1.21 (1H, m), 1.43-1.58 (5H, m), 1.69-1.73 (2H, m), 2.06-2.25 (2H, m), 2.57-2.61 (1H, m), 2.73-2.77 (1H, m), 3.15 (2H, s), 3.19 (3H, s), 3.62 (1H, m), 4.70 (1H, d, J=5.4Hz), 7.06 (2H, m),

		7.19-7.35 (3H, m), 7.52 (1H, d, J=8.4Hz), 7.75 (1H, dd, J=1.8, 8.4Hz), 8.05 (1H, d, J=1.8Hz), 10.08 (1H, s)
Ex. 1-45		(300MHz, DMSO-D6) 1.43-1.59 (6H, m), 1.84-1.90 (2H, m), 2.25-2.32 (2H, m), 2.71-2.75 (2H, m), 3.14 (2H, s), 3.19 (3H, s), 3.21 (1H, br), 3.23 (3H, s), 7.05 (2H, m), 7.19-7.35 (3H, m), 7.50 (1H, d, J=8.4Hz), 7.76 (1H, dd, J=1.8, 8.4Hz), 8.07 (1H, d, J=2.1Hz), 10.07 (1H, s)
Ex. 1-46		(DMSO-D6) 1.41-1.57 (4H, m), 3.16-3.23 (4H, m), 3.43 (3H, s), 3.70-3.79 (4H, m), 7.00-7.12 (4H, m), 7.17-7.732 (3H, m), 7.51-7.79 (2H, m)
Ex. 1-47		(400MHz, CDCl3) 1.40-1.50 (2H, m), 1.60-1.74 (2H, m), 2.22 (3H, s), 3.24 (3H, s), 6.98-7.29 (6H, m), 7.70 (1H, s), 9.24 (1H, d, J=5.6Hz)
Ex. 1-48		(300MHz, DMSO-D6) 1.48-1.67 (4H, m), 3.13-3.22 (4H, m), 3.44-3.63 (7H, m), 4.81 (2H, br. s), 7.13-7.52 (8H, m), 9.35 (2H, br. s)
Ex. 1-49		(400MHz, DMSO-D6) 1.50-1.73 (4H, m), 2.04 (3H, s), 3.23-3.44 (7H, m), 3.55-3.67 (4H, m), 7.01-7.49 (8H, m)
Ex. 1-50		(400MHz, DMSO-D6) 1.41-1.59 (4H, m), 2.88 (3H, s), 3.24 (3H, s), 3.20-3.33 (4H, m), 3.40-3.51 (4H, m), 7.00-7.41 (8H, m)
Ex. 1-51		(300MHz, DMSO-D6) 1.02 (12H, d, J=6.6Hz), 1.52-1.73 (4H, m), 2.92 (1H, septet, J=6.6Hz), 3.29-3.48 (7H, m), 3.55-3.76 (4H, m), 7.06-7.59 (8H, m)
Ex. 1-52		(300MHz, DMSO-D6) 1.50-1.71 (4H, m), 2.78 (6H, s), 3.19-3.40 (7H, m), 7.02-7.48 (8H, m)
Ex. 1-53		(300MHz, DMSO-d6) 1.60 (5H, m), 1.70 (2H, m), 3.28-3.38 (7H, m), 7.08 (1H, dd, J=8.8, 2.2Hz), 7.17-7.19 (3H, m), 7.29 (1H, t, J=7.4Hz), 7.38 (2H, t, J=7.4Hz), 7.46 (1H, d, J=8.8Hz)









Ex.1-54		(300MHz, DMSO-d6) 1.43 (2H, m), 1.59 (2H, m), 1.69 (2H, m), 1.80 (2H, m), 3.12 (2H, m), 3.36 (3H, s), 3.73 (4H, m), 7.08-7.48 (8H, m)
Ex.1-55		(300MHz, DMSO-d6) 1.57 (2H, m), 1.70 (2H, m), 3.32 (4H, t, J=4.8Hz), 3.37 (3H, s), 3.74 (4H, t, J=4.8 Hz), 7.12 (1H, dd, J=8.8, 2.5Hz), 7.18-7.30 (5H, m), 7.49 (1H, d, J=8.8Hz)
Ex.1-56		(300MHz, DMSO-d6) 0.93 (3H, d, J=14.6Hz), 1.18 (2H, m), 1.54-1.69 (7H, m), 2.86 (2H, m), 3.33 (3H, s), 3.90 (2H, m), 7.07 (1H, dd, J=8.8, 1.8Hz), 7.14-7.16 (3H, m), 7.28-7.44 (4H, m)
Ex.1-57		(300MHz, DMSO-d6) 1.60 (2H, m), 1.70 (2H, m), 19.8 (4H, quint, J=3.4Hz), 3.30 (7H, m), 6.68 (1H, dd, J=8.8, 2.4Hz), 6.76 (1H, d, J=2.2Hz), 7.18 (2H, m), 7.29 (2H, m), 7.35 (1H, m), 7.43 (1H, d, J=8.8Hz)
Ex.1-58		(300MHz, DMSO-d6) 1.55-1.64 (5H, m), 1.92 (2H, m), 3.02 (2H, m), 3.38 (3H, s), 3.63 (3H, s), 3.89 (2H, m), 7.12 (1H, dd, J=8.8, 2.4Hz), 7.19-7.21 (2H, m), 7.31 (2H, m), 7.39 (2H, m), 7.49 (1H, d, J=8.8Hz)
Ex.1-59		(300MHz, DMSO-d6) 1.42 (2H, m), 1.52 (2H, m), 1.63 (2H, m), 1.90 (2H, m), 2.94 (2H, m), 3.17 (3H, s), 7.00-7.05 (3H, m), 7.11 (1H, d, J=2.6Hz), 7.22 (1H, m), 7.29-7.34 (3H, m), 12.21 (1H, brs)
Ex.1-60		(300MHz, DMSO-d6) 1.45 (2H, m), 1.53 (2H, m), 1.64 (2H, m), 1.76 (2H, m), 2.33 (1H, m), 2.57 (3H, d, J=3.6Hz), 2.84 (2H, m), 3.17 (3H, s), 3.88 (2H, m), 7.00 (1H, d, J=2.6Hz), 7.04 (2H, m), 7.10 (1H, d, J=2.5Hz), 7.22 (1H, m), 7.32 (3H, m), 7.74 (1H, d,

		$J=4.8\text{Hz}$)
Ex. 1-61		(300MHz, DMSO-d6) 1.45 (2H, m), 1.53 (2H, m), 1.69 (4H, t, $J=5.6\text{Hz}$), 3.30 (3H, s), 3.43 (4H, t, $J=5.6\text{Hz}$), 3.92 (4H, s), 7.01-7.05 (3H, m), 7.14 (1H, d, $J=2.5\text{Hz}$), 7.22 (1H, tt, $J=7.4, 2.2\text{Hz}$), 7.29-7.34 (3H, m)
Ex. 1-62		(300MHz, DMSO-d6) 1.55-1.71 (5H, m), 1.92 (2H, m), 3.01 (2H, m), 3.26 (3H, s), 3.34 (3H, s), 3.53 (2H, t, $J=4.8\text{Hz}$), 3.86 (2H, m), 4.16 (2H, t, $J=4.6\text{Hz}$), 7.10 (1H, dd, $J=8.8, 2.6\text{Hz}$), 7.08-7.11 (3H, m), 7.29 (1H, m), 7.37 (2H, m), 7.46 (1H, d, $J=8.8\text{Hz}$)
Ex. 1-63		(300MHz, DMSO-d6) 1.34-1.56 (16H, m), 1.78 (2H, m), 2.89 (2H, m), 3.26 (3H, s), 3.80 (2H, m), 6.85 (1H, brs), 6.99 (1H, d, $J=2.6\text{Hz}$), 7.03 (2H, m), 7.10 (1H, d, $J=2.6\text{Hz}$), 7.22 (1H, tt, $J=7.3, 2.2\text{Hz}$), 7.30-7.42 (3H, m)
Ex. 1-64		(300MHz, DMSO-d6) 1.53-1.68 (6H, m), 1.99 (2H, m), 2.96 (2H, m), 3.25-3.30 (4H, m), 3.98 (2H, m), 7.08 (1H, d, $J=2.2\text{Hz}$), 7.13 (2H, m), 7.21 (1H, d, $J=2.2\text{Hz}$), 7.26 (1H, m), 7.39 (2H, m), 7.45 (1H, d, $J=8.8\text{Hz}$), 8.29 (2H, brs)
Ex. 1-65		(300MHz, DMSO-d6) 1.43-1.48 (4H, m), 1.53 (2H, m), 1.79-1.83 (5H, m), 2.98 (2H, m), 3.30 (3H, s), 3.79-3.83 (3H, m), 7.00-7.05 (3H, m), 7.12 (1H, d, $J=2.2\text{Hz}$), 7.22 (1H, m), 7.29-7.34 (3H, m), 7.79 (1H, d, $J=7.7\text{Hz}$)
Ex. 1-66		(300MHz, DMSO-d6) 1.38-1.55 (4H, m), 1.64 (2H, m), 1.72-1.88 (2H, m), 2.83 (1H, m), 2.96 (1H, m), 3.30 (3H, s), 3.52-3.70 (4H, m), 7.01 (1H, dd, $J=8.8, 2.4\text{Hz}$), 7.09 (1H, d, $J=2.6\text{Hz}$), 7.11 (2H, m), 7.24 (1H, tt, $J=7.2, 2.1\text{Hz}$), 7.32 (2H, m), 7.39 (1H, d, $J=8.9\text{Hz}$)












Ex. 1-67		(300MHz, DMSO-D6) 1.42-1.59 (4H, m), 3.17 (3H, s), 3.76 (3H, s), 5.14 (2H, s), 6.93-7.51 (12H, m)
Ex. 1-68		(400MHz, DMSO-D6) 1.47-1.72 (4H, m), 3.29 (3H, s), 6.93-7.51 (8H, m), 10.74 (1H, br. s)
Ex. 1-69		(300MHz, DMSO-D6) 1.49-1.73 (4H, m), 3.29 (3H, s), 4.59 (2H, s), 6.16 (1H, br. s), 7.08-7.67 (10H, m)
Ex. 1-70		(300MHz, DMSO-D6), 1.51-1.55 (2H, m), 1.62-1.66 (2H, m), 3.28 (3H, s), 7.10-7.13 (2H, m), 7.22-7.27 (1H, m), 7.32-7.37 (2H, m), 7.81 (1H, d, J=7.9Hz), 8.08 (1H, dd, J=1.5, 7.9Hz), 8.14 (1H, d, J=1.5Hz)
Ex. 1-71		(300MHz, DMSO-D6), 1.51-1.55 (2H, m), 1.62-1.66 (2H, m), 3.30 (3H, s), 3.38 (3H, s), 7.11-7.13 (2H, m), 7.23-7.28 (1H, m), 7.33-7.38 (2H, m), 7.94 (1H, d, J=8.1Hz), 8.09 (1H, dd, J=1.6, 8.1Hz), 8.24 (1H, d, J=1.6Hz)
Ex. 1-72		(300MHz, DMSO-D6), 1.46-1.51 (2H, m), 1.54-1.60 (2H, m), 3.22 (3H, s), 7.05-7.08 (2H, m), 7.20-7.25 (1H, m), 7.30-7.36 (2H, m), 7.74 (1H, d, J=8.1Hz), 8.03 (1H, dd, J=1.4, 8.1Hz), 8.09 (1H, d, J=1.4Hz)
Ex. 1-73		(300MHz, DMSO-D6), 1.46-1.49 (2H, m), 1.55-1.59 (2H, m), 3.21 (3H, s), 7.05-7.08 (2H, m), 7.20-7.25 (1H, m), 7.30-7.35 (2H, m), 7.66 (1H, brs), 7.69 (1H, d, J=8.1Hz), 7.98 (1H, dd, J=1.6, 8.1Hz), 8.11 (1H, d, J=1.6Hz), 8.21 (1H, brs)
Ex. 1-74		(300MHz, DMSO-D6), 1.50-1.54 (2H, m), 1.60-1.64 (2H, m), 3.28 (3H, s), 3.37 (2H, brs), 3.63 (6H, brs), 7.09-7.12 (2H, m), 7.22-7.27 (1H, m), 7.32-7.37 (2H, m), 7.57 (1H, dd, J=1.5, 7.8Hz), 7.70 (1H, d, J=7.8Hz), 7.74 (1H, d, J=1.5Hz)

Ex.1-81		(300MHz, DMSO-D6), 1.40 (2H, brs), 1.45-1.51 (2H, m), 1.54-1.59 (2H, m), 1.76 (2H, brs), 3.22 (5H, brs), 3.48 (1H, brs), 3.75 (1H, m), 3.98 (1H, brs), 4.79 (1H, d, J=4.2Hz), 7.05-7.07 (2H, m), 7.20-7.25 (1H, m), 7.30-7.35 (2H, m), 7.50 (1H, dd, J=1.6, 7.6Hz), 7.64 (1H, d, J=7.6Hz), 7.66 (1H, d, J=1.6Hz)
Ex.1-82		(300MHz, DMSO-D6), 1.46-1.51 (2H, m), 1.54-1.59 (2H, m), 3.21 (3H, s), 3.84 (2H, d, J=5.7Hz), 7.06-7.09 (3H, m), 7.20-7.25 (1H, m), 7.31-7.36 (2H, m), 7.42 (1H, brs), 7.71 (1H, d, J=8.0Hz), 7.98 (1H, dd, J=1.8, 8.0Hz), 8.14 (1H, d, J=1.8Hz), 8.96 (1H, t, J=5.7Hz)
Ex.1-83		(300MHz, DMSO-D6), 1.52-1.56 (2H, m), 1.59-1.64 (2H, m), 3.27 (3H, s), 4.14 (2H, m), 7.10-7.13 (2H, m), 7.22-7.27 (1H, m), 7.32-7.37 (2H, m), 7.78 (1H, d, J=8.0Hz), 8.04 (1H, dd, J=1.5, 8.0Hz), 8.17 (1H, d, J=1.5Hz), 9.42 (1H, t, J=6.3Hz)
Ex.1-84		(300MHz, DMSO-D6), 1.50-1.55 (2H, m), 1.58-1.64 (2H, m), 1.91 (3H, s), 3.21-3.34 (4H, m), 3.26 (3H, s), 7.10-7.12 (2H, m), 7.22-7.27 (1H, m), 7.32-7.37 (2H, m), 7.74 (1H, d, J=8.1Hz), 7.96-8.00 (2H, m), 8.11 (1H, d, J=1.8Hz), 8.82 (1H, t, J=6.2Hz)
Ex.1-85		(300MHz, DMSO-D6), 1.49-1.55 (2H, m), 1.58-1.63 (2H, m), 3.25 (3H, s), 3.27 (3H, s), 3.42-3.50 (4H, m), 7.09-7.11 (2H, m), 7.22-7.27 (1H, m), 7.32-7.37 (2H, m), 7.73 (1H, d, J=7.8Hz), 7.99 (1H, dd, J=1.5, 7.8Hz), 8.12 (1H, d, J=1.5Hz), 8.82 (1H, brs)
Ex.1-86		(300MHz, DMSO-D6), 1.51-1.57 (2H, m), 1.60-1.66 (2H, m), 2.03 (3H, s), 3.20-3.70 (8H, m), 3.29 (3H, s), 7.10-7.12 (2H, m), 7.23-7.27 (1H, m), 7.32-7.37 (2H, m), 7.58 (1H, dd, J=1.5, 8.0Hz),













		7.72 (1H, d, J=8.0Hz), 7.76 (1H, d, J=1.5Hz)
Ex.1-87		(300MHz, DMSO-D6), 1.45-1.50 (2H, m), 1.54-1.59 (2H, m), 2.18 (6H, s), 2.41 (2H, t, J=6.4Hz), 3.21 (3H, s), 3.38 (2H, dt, J=6.4, 6.4Hz), 7.05-7.08 (2H, m), 7.20-7.25 (1H, m), 7.30-7.35 (2H, m), 7.69 (1H, d, J=7.8Hz), 7.94 (1H, dd, J=1.9, 7.8Hz), 8.08 (1H, d, J=1.9Hz), 8.65 (1H, t, 6.4Hz)
Ex.1-88		(300MHz, DMSO-D6), 1.46-1.51 (2H, m), 1.54-1.59 (2H, m), 2.40-2.43 (4H, m), 2.48-2.51 (2H, m), 3.21 (3H, s), 3.41 (2H, dt, J=5.9, 5.9Hz), 3.55-3.59 (4H, m), 7.06-7.08 (2H, m), 7.20-7.25 (1H, m), 7.31-7.35 (2H, m), 7.70 (1H, d, J=8.0Hz), 7.94 (1H, dd, J=1.5, 8.0Hz), 8.07 (1H, d, J=1.5Hz), 8.68 (1H, t, J=5.9Hz)
Ex.1-89		(300MHz, DMSO-d6) 1.56 (2H, m), 1.66 (2H, m), 3.02 (6H, s), 3.32 (3H, s), 6.83 (1H, dd, J=8.8, 2.6 Hz), 6.91 (1H, d, J=1.5 Hz), 7.15 (2H, m), 7.27 (1H, m), 7.37 (1H, t, 7.4Hz), 7.42 (1H, d, 8.8Hz)
Ex.1-90		(300MHz, DMSO-d6) 1.57 (2H, m), 1.66 (2H, m), 3.30 (4H, t, J=4.9Hz), 3.32 (3H, s) 3.74 (4H, t, J=4.9Hz), 7.09 (1H, dd, J=8.8, 2.6Hz), 7.14-7.37 (6H, m), 7.48 (1H, d, J=7.2Hz)
Ex.1-91		(300MHz, DMSO-d6) 1.57 (2H, m), 1.691 (2H, m), 3.34 (3H, s), 3.85 (3H, s), 7.17 (2H, d, J=7.6Hz), 7.26-7.31 (2H, m), 7.38 (3H, t, J=7.4Hz), 7.56 (1H, d, J=8.1Hz)

Ex.1-92		(300MHz, DMSO-d6) 1.57 (2H, m), 1.68 (2H, m), 3.31 (3H, s), 7.15 (2H, m), 7.27 (1H, tt, J=7.4, 2.2Hz), 7.36 (2H, m), 7.50 (1H, m), 7.74-7.80 (2H, m)
Ex.1-93		(300MHz, DMSO-d6) 1.52 (2H, m), 1.58 (2H, m), 3.27 (3H, s), 7.09-7.12 (2H, m), 7.25 (1H, m), 7.32-7.35 (2H, m), 7.86 (1H, d, J=8.1Hz), 8.08 (1H, dd, J=8.1, 2.2Hz), 8.41 (1H, d, J=2.2Hz)
Ex.1-94		(300MHz, DMSO-d6) 1.56 (2H, m), 1.74 (2H, m), 3.40 (3H, s), 5.20 (2H, brs), 6.74 (1H, dd, J=8.4, 2.2 Hz), 6.93 (1H, d, J=2.2 Hz), 7.25-7.38 (6H, m)
Ex.1-95		(300MHz, DMSO-d6) 1.53 (2H, m), 1.62 (2H, m), 3.36 (3H, d, J=1.5Hz), 7.13-7.16 (2H, m), 7.25 (1H, tt, J=7.4, 2.8Hz), 7.31-7.37 (2H, m), 7.53 (1H, dd, J=7.7, 3.4Hz), 7.69-7.76 (2H, m)
Ex.1-96		(300MHz, DMSO-D6) 1.49-1.55 (2H, m), 1.58-1.63 (2H, m), 3.30 (3H, s), 7.10-7.13 (2H, m), 7.22-7.27 (1H, m), 7.32-7.37 (2H, m), 7.71 (1H, d, J=4.5Hz), 8.75 (1H, d, J=4.5Hz), 8.90 (1H, s)
Ex.1-97		(300MHz, DMSO-D6) 1.46-1.50 (2H, m), 1.54-1.58 (2H, m), 3.26 (3H, s), 7.06-7.09 (2H, m), 7.20-7.25 (1H, m), 7.30-7.35 (2H, m), 7.79 (1H, d, J=8.1Hz), 8.17 (1H, d, J=8.1Hz)
Ex.1-98		(300MHz, DMSO-D6) 1.56-1.72 (4H, m), 3.86 (3H, s), 7.13-7.18 (2H, m), 7.23-7.37 (3H, m), 7.57-7.62 (1H, m), 8.03-8.10 (1H, m), 8.15-8.21 (1H, m), 8.72-8.76 (1H, m)
Ex.1-99		









Ex.1-100	<p>Chemical structure of Ex.1-100: 2-(4-bromo-2-chlorophenyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-101	<p>Chemical structure of Ex.1-101: 2-(4-phenylphenyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-102	<p>Chemical structure of Ex.1-102: 2-(4-(2,2,2-trifluoroethyl)phenyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-103	<p>Chemical structure of Ex.1-103: 2-(cyclohexyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-104	<p>Chemical structure of Ex.1-104: 2-(2-methylcyclohexyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-105	<p>Chemical structure of Ex.1-105: 2-(2-hydroxycyclohexyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-106	<p>Chemical structure of Ex.1-106: 2-(4-chlorophenyl)-4-(1-(4-fluorophenyl)cyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-107	<p>Chemical structure of Ex.1-107: 2-(4-chlorophenyl)-4-(1-(4-fluorophenyl)cyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-108	<p>Chemical structure of Ex.1-108: 2-(4-hydroxycyclohexyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	
Ex.1-109	<p>Chemical structure of Ex.1-109: 2-(4-(2-aminocyclohexyl)phenyl)-4-(1-phenylcyclopropyl)-1-methyl-1,2-dihydro-4H-1,2-diazepine.</p>	

Ex.1-110		
Ex.1-111		
Ex.1-112		
Ex.1-113		
Ex.1-114		
Ex.1-115		
Ex.1-116		
Ex.1-117		
Ex.1-118		
Ex.1-119		
Ex.1-120		
Ex.1-121		

Ex.1-122		
Ex.1-123		
Ex.1-124		
Ex.1-125		
Ex.1-126		
Ex.1-127		
Ex.1-128		
Ex.1-129		
Ex.1-130		
Ex.1-131		
Ex.1-132		

Ex.1-133		
Ex.1-134		
Ex.1-135		
Ex.1-136		
Ex.1-137		
Ex.1-138		
Ex.1-139		
Ex.1-140		
Ex.1-141		
Ex.1-142		
Ex.1-143		
Ex.1-144		

Ex.1-145		
Ex.1-146		
Ex.1-147		
Ex.1-148		
Ex.2-1		300MHz, DMSO-d ₆ , 1.50-1.66 (4H, m), 1.76-1.91 (4H, m), 2.70-2.80 (1H, m), 3.19-3.28 (2H, m), 3.43 (3H, s), 3.77 (2H, d, J=12.8Hz), 7.20-7.39 (10H, m)
Ex.2-2		400MHz, DMSO-d ₆ , 1.48-1.60 (4H, m), 2.07-2.15 (2H, m), 2.51-2.55 (5H, m), 3.19 (2H, t, J=11.6Hz), 3.57 (2H, brd, J=13.7Hz), 3.64 (3H, s), 7.15-7.40 (10H, m)
Ex.2-3		400MHz, DMSO-d ₆ , 1.34-1.48 (4H, m), 1.96-2.06 (2H, m), 2.50 (2H, m), 2.99 (2H, t, J=11.7Hz), 3.22 (3H, s), 3.31 (2H, brd, J=12.5Hz), 7.03-7.45 (10H, m)
Ex.2-4		400MHz, DMSO-d ₆ , 1.37-1.50 (4H, m), 1.67-1.77 (2H, m), 1.88-1.93 (2H, m), 2.55-2.62 (1H, m), 2.89-2.95 (2H, m), 3.22 (3H, s), 3.33-3.37 (2H, m), 3.62 (3H, s), 7.04-7.31 (5H, m)
Ex.2-5		400MHz, DMSO-d ₆ , 1.32-1.46 (4H, m), 1.62-1.75 (2H, m), 1.86-1.91 (2H, m), 2.37-2.46 (1H, m), 2.79-2.88 (2H, m), 3.18 (3H, s), 3.23-3.30 (2H, m), 7.02-7.32 (5H, m), 12.2 (1H, br.s)

Ex. 2-6		400MHz, DMSO-d6, 1.21-1.57(7H, m), 1.68-1.75(2H, m), 2.75(2H, dt, J=2.4, 12.0Hz), 3.17(3H, s), 3.24-3.37(4H, m), 4.49(1H, t, J=5.2Hz), 7.00-7.04(2H, m), 7.16-7.21(1H, m), 7.26-7.31(2H, m)
Ex. 2-7		400MHz, DMSO-d6, 1.35-1.64(14H, m), 1.98-2.05(2H, m), 2.99-3.07(2H, m), 3.08(3H, s), 3.26-3.32(2H, m), 7.10-7.28(5H, m)
Ex. 2-8		400MHz, DMSO-d6, 1.48-1.62(4H, m), 1.68-1.79(2H, m), 1.99-2.07(2H, m), 3.09-3.18(2H, m), 3.25-3.38(4H, m), 3.61-3.68(2H, m), 7.17-7.36(5H, m), 8.39(2H, brs)
Ex. 2-9		300MHz, DMSO-d6, 1.33-1.60(6H, m), 1.75-1.85(5H, m), 2.81-2.91(2H, m), 3.18(3H, s), 3.24-3.35(2H, m), 3.65-3.77(1H, m), 7.01-7.07(2H, m), 7.16-7.24(1H, m), 7.26-7.34(2H, m), 7.85(1H, d, J=7.7Hz)
Ex. 2-10		300MHz, DMSO-d6, 1.33-1.46(4H, m), 1.59-1.73(2H, m), 1.86-1.97(2H, m), 2.92(2H, t, J=10.6Hz), 3.19(3H, s), 3.27-3.37(2H, m), 3.88-3.97(1H, m), 7.00-7.68(8H, m), 8.52(1H, d, J=7.7Hz)
Ex. 2-11		300MHz, DMSO-d6, 1.33-1.47(14H, m), 1.54-1.64(2H, m), 1.85(2H, m), 2.70(3H, s), 2.85(2H, m), 3.19(3H, s), 3.29-3.40(2H, m), 7.01-7.06(2H, m), 7.16-7.23(1H, m), 7.27-7.34(2H, m)
Ex. 2-12		400MHz, DMSO-d6, 1.48-1.64(4H, m), 1.71-1.83(2H, m), 2.09-2.18(2H, m), 2.49-2.53(3H, m), 3.04-3.27(3H, m), 3.37(3H, s), 3.65-3.72(2H, m), 7.17-7.37(5H, m), 9.45(2H, brs)
Ex. 2-13		300MHz, DMSO-d6, 120°C, 1.30-1.47(4H, m), 1.55-1.63(2H, m), 1.80-1.96(2H, m), 2.01(3H, s), 2.79(3H, s), 2.88-3.00(2H, m), 3.19(3H, s), 3.31-3.39(2H, m), 7.05-7.10(2H, m), 7.15-7.21(1H, m), 7.25-7.31(2H, m),

Ex. 2-14		300MHz, DMSO-d6, 1.45-1.71(10H, m), 3.27-3.41(7H, m), 7.16-7.39(5H, m)
Ex. 2-15		300MHz, DMSO-d6, 1.48-1.73(6H, m), 1.86-1.96(2H, m), 2.61-2.73(1H, m), 3.07-3.18(2H, m), 3.38(3H, s), 3.68(2H, m), 7.18-7.39(5H, m)
Ex. 2-16		400MHz, DMSO-d6, 1.32-1.46(4H, m), 1.62-1.80(4H, m), 2.21-2.30(1H, m), 2.72-2.82(2H, m), 3.17(3H, s), 3.27-3.31(2H, m), 6.76(1H, bs), 7.00-7.05(2H, m), 7.17-7.20(1H, m), 7.25-7.31(3H, m)
Ex. 2-17		300MHz, DMSO-d6, 1.30-1.45(4H, m), 1.93-2.22(4H, m), 2.83(2H, t, J=10.1Hz), 3.09-3.20(5H, m), 3.38(2H, d, J=5.5Hz), 4.66(1H, t, J=5.3Hz), 6.97-7.04(2H, m), 7.15-7.43(3H, m)
Ex. 2-18		300MHz, DMSO-d6, 1.32-1.46(4H, m), 1.66-1.77(4H, m), 2.20-2.31(1H, m), 2.57(3H, d, J=4.8Hz), 2.72-2.82(2H, m), 3.18(3H, s), 3.26-3.34(2H, m), 7.00-7.06(2H, m), 7.16-7.23(1H, m), 7.26-7.33(2H, m), 7.72(1H, d, J=4.4Hz)
Ex. 2-19		300MHz, DMSO-d6, 1.31-1.47(4H, m), 1.64-1.75(4H, m), 2.75-2.92(6H, m), 3.04(3H, s), 3.18(3H, s), 3.26-3.34(5H, s), 7.01-7.06(2H, m), 7.16-7.22(1H, m), 7.26-7.33(2H, m)
Ex. 2-20		300MHz, DMSO-d6, 1.47-1.64(4H, m), 3.28-3.35(4H, m), 3.40(3H, s), 3.71-3.78(4H, m), 7.17-7.39(5H, m)
Ex. 2-21		300MHz, DMSO-d6, 1.47-1.63(4H, m), 2.74-2.81(4H, m), 3.37(3H, s), 3.51-3.58(4H, m), 7.17-7.39(5H, m)

Ex. 2-31		(300MHz, DMSO-D6), 1.47-1.62 (4H, m), 1.84-1.95 (2H, m), 2.05-2.21 (2H, m), 3.32-3.43 (2H, m), 3.41 (3H, s), 3.49-3.60 (2H, m), 5.33-5.35 (1H, m), 7.14-7.22 (2H, m), 7.26-7.33 (2H, m), 8.20 (1H, d, J=2.6Hz), 8.22 (1H, d, J=2.6Hz)
Ex. 2-32		(300MHz, CDCl3), 1.35-1.58 (4H, m), 1.63-1.79 (2H, m), 1.97-2.05 (2H, m), 2.96-3.05 (2H, m), 3.20 (3H, s), 3.30-3.37 (2H, m), 3.85-3.91 (1H, m), 7.12-7.31 (5H, m)
Ex. 2-33		(400MHz, DMSO-D6), 1.48-1.67 (4H, m), 1.72-1.85 (2H, m), 1.89-2.00 (2H, m), 3.17-3.27 (2H, m), 3.40 (3H, s), 3.61-3.71 (2H, m), 4.15 (1H, brs), 6.46-6.48 (1H, m), 7.18-7.38 (5H, m), 7.83 (1H, d, J=1.8Hz), 8.04 (1H, d, J=1.8Hz)
Ex. 2-34		(400MHz, DMSO-D6), 1.27-1.83 (9H, m), 2.56 (2H, d, J=11.4Hz), 2.95-3.04 (2H, m), 3.34 (3H, s), 3.55-3.62 (2H, m), 7.15-7.35 (5H, m), HCl
Ex. 2-35		(300MHz, DMSO-D6), 1.46-1.63 (4H, m), 1.73-1.87 (2H, m), 2.02-2.14 (2H, m), 3.25-3.37 (2H, m), 3.39 (3H, s), 3.50-3.61 (2H, m), 4.66-4.68 (1H, m), 7.01-7.08 (2H, m), 7.19-7.38 (7H, m), HCl
Ex. 2-36		(300MHz, DMSO-D6), 1.46-1.62 (4H, m), 1.78-1.91 (2H, m), 2.01-2.13 (2H, m), 3.24-3.36 (2H, m), 3.38 (3H, s), 3.47-3.58 (2H, m), 4.72-4.74 (1H, m), 7.15-7.49 (8H, m), HCl
Ex. 2-37		(400MHz, DMSO-D6), 1.46-1.67 (4H, m), 1.87-2.03 (2H, m), 2.09-2.22 (2H, m), 3.33-3.46 (2H, m), 3.40 (3H, s), 3.49-3.60 (2H, m), 5.46-5.48 (1H, m), 7.18-7.40 (5H, m), 8.41-8.43 (1H, m), 8.57-8.59 (1H, m), HCl
Ex. 2-38		(300MHz, DMSO-D6), 1.47-1.63 (4H, m), 1.83-1.97 (2H, m), 2.07-2.18 (2H, m), 3.30-3.42 (2H, m), 3.40 (3H, s), 3.49-3.59 (2H, m), 5.37-5.39 (1H, m), 7.03-7.07 (1H, m), 7.17-7.40 (5H, m), 7.92-7.94 (1H, m), 8.14-8.16 (1H, m), HCl

Ex. 2-39		(300MHz, DMSO-D6), 1.47-1.63 (4H, m), 1.77-1.92 (2H, m), 2.06-2.19 (2H, m), 3.26-3.41 (2H, m), 3.39 (3H, s), 3.50-3.61 (2H, m), 5.21-5.23 (1H, m), 6.88 (1H, d, J=9.6Hz), 7.17-7.39 (5H, m), 7.82 (1H, dd, J=3Hz, 8.7Hz), 8.22 (1H, d, J=2.4Hz)
Ex. 2-40		(300MHz, DMSO-D6), 1.31-1.50 (4H, m), 1.62-1.73 (2H, m), 2.04-2.18 (2H, m), 3.11-3.35 (4H, m), 3.23 (3H, s), 5.04 (1H, s), 7.03-7.06 (2H, m), 7.17-7.38 (5H, m), 7.49-7.56 (2H, m)
Ex. 2-41		(300MHz, DMSO-D6), 1.46-1.66 (4H, m), 1.74-1.86 (2H, m), 1.90-2.07 (2H, m), 2.81 (3H, s), 3.11-3.24 (2H, m), 3.42 (3H, s), 3.67-3.78 (2H, m), 3.87-3.89 (1H, m), 7.19-7.40 (5H, m), 8.02 (1H, d, J=2.7Hz), 8.24 (1H, d, J=2.1Hz)
Ex. 2-42		(300MHz, DMSO-D6), 1.45-1.64 (4H, m), 2.06-2.13 (4H, m), 2.93 (3H, s), 3.41 (3H, s), 3.43-3.56 (4H, m), 7.16-7.46 (10H, m)
Ex. 2-43		(300MHz, DMSO-D6), 1.45-1.70 (6H, m), 1.90-2.01 (2H, m), 3.11-3.23 (2H, m), 3.28 (3H, s), 3.37 (3H, s), 3.40- 3.52 (3H, m), 7.15-7.39 (5H, m)
Ex. 2-44		(300MHz, DMSO-D6), 1.31-1.49 (4H, m), 1.70-1.88 (2H, m), 2.02-2.15 (2H, m), 2.97-3.08 (2H, m), 3.21 (3H, s), 3.24-3.36 (2H, m), 4.66-4.77 (1H, m), 7.01-7.35 (7H, m), 7.88 (2H, d, J=9.0Hz)
Ex. 2-45		(300MHz, DMSO-D6), 1.31-1.49 (4H, m), 1.71-1.87 (2H, m), 2.00-2.12 (2H, m), 2.96-3.15 (2H, m), 3.21 (3H, s), 3.23-3.36 (2H, m), 4.62-4.73 (1H, m), 7.02-7.58 (9H, m)
Ex. 2-46		(300MHz, DMSO-D6), 1.31-1.48 (4H, m), 1.73-1.89 (2H, m), 1.95-2.09 (2H, m), 2.97-3.07 (2H, m), 3.20 (3H, s), 3.26-3.37 (2H, m), 4.67-4.76 (1H, m), 6.96-7.64 (9H, m)
Ex. 2-47		(300MHz, DMSO-D6), 1.45-1.65 (4H, m), 1.75-1.90 (2H, m), 2.03-2.18 (2H, m), 3.25-3.58 (4H, m), 3.37 (3H, s),


		4.70-4.79 (1H, m), 7.12-7.47 (9H, m), 8.40-8.47 (1H, m)
Ex. 2-57		(300MHz, DMSO-D6), 1.47-1.66 (4H, m), 1.74-1.88 (2H, m), 2.01-2.16 (2H, m), 2.88-3.00 (6H, m), 3.29-3.39 (2H, m), 3.41 (3H, s), 3.51-3.63 (2H, m), 4.69-4.79 (1H, m), 6.91-7.40 (9H, m)
Ex. 2-58		(300MHz, DMSO-D6), 0.99 (6H, s), 1.39-1.64 (8H, m), 3.30-3.41 (4H, m), 3.38 (3H, s), 7.16-7.40 (5H, m)
Ex. 2-59		(300MHz, DMSO-D6), 1.18 (3H, s), 1.44-1.71 (8H, m), 3.31-3.39 (4H, m), 3.36 (3H, s), 7.14-7.39 (5H, m)
Ex. 2-60		(300MHz, DMSO-D6), 0.98 (6H, s), 1.41-1.62 (8H, m), 3.28-3.35 (4H, m), 3.37 (3H, s), 7.13-7.30 (4H, m)
Ex. 2-61		(300MHz, DMSO-D6), 1.21-1.82 (11H, m), 2.96-3.08 (2H, m), 3.35 (3H, s), 3.47 (2H, t, J=6.6Hz), 3.52-3.62 (2H, m), 7.14-7.38 (5H, m)
Ex. 2-62		(300MHz, DMSO-D6), 1.46-1.65 (4H, m), 1.73-1.88 (2H, m), 2.01-2.16 (2H, m), 3.26-3.36 (2H, m), 3.40 (3H, s), 3.49-3.61 (2H, m), 3.86 (3H, s), 4.71-4.79 (1H, m), 7.17-7.51 (8H, m)
Ex. 2-63		(300MHz, DMSO-D6), 1.32-1.49 (4H, m), 1.70-1.85 (2H, m), 2.00-2.10 (2H, m), 2.96-3.08 (2H, m), 3.21 (3H, s), 3.23-3.36 (2H, m), 4.50 (2H, d, J=6.0Hz), 4.54-4.64 (1H, m), 5.36 (1H, t, J=5.7Hz), 6.88-7.38 (8H, m)
Ex. 2-64		(300MHz, DMSO-D6), 1.31-1.49 (4H, m), 1.69-1.85 (2H, m), 1.97-2.10 (2H, m), 2.97-3.08 (2H, m), 3.20 (3H, s), 3.23-3.34 (2H, m), 4.60-4.71 (1H, m), 7.00-7.48 (8H, m)
Ex. 2-65		(300MHz, DMSO-D6), 0.87 (6H, d, J=6.9Hz), 1.26-1.78 (9H, m), 2.96-3.08 (2H, m), 3.37 (3H, s), 3.60-3.71 (2H, m), 7.15-7.40 (5H, m)

Ex. 2-66		(300MHz, DMSO-D6), 1.32-1.48 (4H, m), 1.68-1.84 (2H, m), 1.97-2.10 (2H, m), 2.96-3.07 (2H, m), 3.20 (3H, s), 3.24-3.36 (2H, m), 4.58-4.70 (1H, m), 7.01-7.38 (8H, m), 7.54 (1H, brs), 7.82 (1H, brs)
Ex. 2-67		(300MHz, DMSO-D6), 1.22 (3H, s), 1.45-1.70 (6H, m), 2.01-2.16 (2H, m), 3.07-3.19 (2H, m), 3.37 (3H, s), 3.40-3.51 (2H, m), 3.67 (3H, s), 7.15-7.39 (5H, m)
Ex. 2-68		(400MHz, DMSO-D6), 0.93 (3H, s), 1.29-1.38 (2H, m), 1.46-1.67 (6H, m), 3.21 (2H, s), 3.22-3.31 (2H, m), 3.34-3.44 (2H, m), 3.36 (3H, s), 7.18-7.34 (5H, m)
Ex. 2-69		(400MHz, DMSO-D6), 1.17 (3H, s), 1.33-1.57 (6H, m), 1.99-2.07 (2H, m), 2.83-2.92 (2H, m), 3.11-3.19 (2H, m), 3.18 (3H, s), 6.99-7.04 (2H, m), 7.17-7.22 (1H, m), 7.25-7.31 (2H, m), 12.36 (1H, brs)
Ex. 2-70		(400MHz, DMSO-D6), 1.12 (3H, s), 1.30-1.54 (6H, m), 1.98-2.12 (2H, m), 2.84-2.93 (2H, m), 3.03-3.10 (2H, m), 3.16 (3H, s), 6.90 (1H, brs), 6.97-7.03 (2H, m), 7.15-7.23 (2H, m), 7.24-7.32 (2H, m)
Ex. 2-71		(DMSO-D6) 0.65 (3H, t, J=7.2Hz), 1.39-1.63 (6H, m), 1.83-1.95 (2H, m), 2.06-2.19 (2H, m), 3.27-3.37 (2H, m), 3.44-3.55 (2H, m), 3.77 (2H, t, J=7.2Hz), 5.27-5.35 (1H, m), 7.21-7.38 (5H, m), 8.18-8.23 (2H, m)
Ex. 2-72		(DMSO-D6) 1.44-1.68 (4H, m), 1.81-1.98 (2H, m), 2.04-2.19 (2H, m), 3.06 (3H, s), 3.24-3.63 (6H, m), 3.44-3.55 (2H, m), 3.77 (2H, t, J=7.2Hz), 4.04 (2H, t, J=5.9Hz), 5.25-5.38 (1H, m), 7.14-7.42 (5H, m), 8.16-8.27 (2H, m)
Ex. 2-73		(DMSO-D6) 1.42-1.63 (4H, m), 1.79-1.92 (2H, m), 2.01-2.16 (2H, m), 3.26-3.41 (5H, m), 3.50-3.68 (2H, m), 4.77-4.83 (1H, m), 7.15-7.42 (7H, m), 7.57-7.62 (1H, m)

Ex. 2-74		(DMSO-D6) 1.47-1.59 (2H, m), 1.63-1.77 (2H, m), 2.07-2.18 (2H, m), 3.34-3.45 (2H, m), 3.56-3.67 (4H, m), 3.90-4.00 (2H, m), 5.29-5.38 (1H, m), 7.17-7.39 (5H, m), 8.20-8.27 (2H, m)
Ex. 2-75		(DMSO-D6) 1.43-1.66 (4H, m), 1.80-1.94 (2H, m), 2.01-2.17 (2H, m), 3.28-3.40 (2H, m), 3.49-3.59 (2H, m), 4.43-4.57 (2H, m), 5.02-5.18 (2H, m), 5.27-5.36 (1H, m), 5.57-5.71 (1H, m), 7.18-7.19 (5H, m), 8.18-8.26 (2H, m)
Ex. 2-76		(DMSO-D6) -0.05-0.06 (2H, m), 0.32-0.41 (2H, m), 0.97-1.10 (1H, m), 1.50-1.66 (4H, m), 1.88-1.96 (2H, m), 2.07-2.19 (2H, m), 3.26-3.40 (2H, m), 3.48-3.57 (2H, m), 3.77 (2H, d, J=6.0Hz), 5.26-5.33 (1H, m), 7.21-7.40 (5H, m), 8.16-8.26 (2H, m)
Ex. 2-77		(DMSO-D6) 0.59 (6H, d, J=6.7Hz), 1.48-1.65 (4H, m), 1.79-1.95 (2H, m), 2.00-2.15 (3H, m), 3.23-3.35 (2H, m), 3.38-3.53 (2H, m), 3.66 (2H, d, J=7.4Hz), 5.26-5.37 (1H, m), 7.12-7.40 (5H, m), 8.18-8.23 (2H, m)
Ex. 2-78		(DMSO-D6) 0.88-1.16 (4H, m), 1.46-1.73 (4H, m), 1.83-2.00 (2H, m), 2.08-2.11 (2H, m), 2.60-2.72 (1H, m), 3.20-3.90 (4H, m), 5.29-5.40 (1H, m), 7.21-7.40 (5H, m), 8.19-8.26 (2H, m)
Ex. 2-79		(DMSO-D6) 1.00 (3H, t, J=7.2Hz), 1.33-1.49 (4H, m), 1.79-1.92 (2H, m), 2.03-2.12 (2H, m), 3.22-3.34 (2H, m), 3.66 (2H, q, J=7.2Hz), 5.21-5.30 (1H, m), 7.05-7.33 (5H, m), 8.15-8.23 (2H, m)
Ex. 2-80		(DMSO-D6) 1.28 (6H, d, J=5.7Hz), 1.50-1.66 (4H, m), 1.82-1.97 (2H, m), 2.03-2.18 (2H, m), 3.07-3.19 (2H, m), 3.26-3.38 (2H, m), 4.43 (1H, septet, J=5.7Hz), 5.24-5.35 (1H, m), 7.12-7.40 (5H, m), 8.18-8.23 (2H, m)
Ex. 2-81		400MHz, DMSO-d6, 1.67-1.81 (4H, m); 1.83-1.94 (2H, m), 2.05-2.17 (2H, m), 2.19-2.28 (2H, m), 2.41-2.52 (2H, m), 3.12 (3H, s), 3.29-3.39 (2H, m), 3.44-3.55 (2H, m), 5.27-5.29 (1H, m),

		7.22-7.33 (3H, m), 7.35-7.42 (2H, m), 2. 19 (1H, d, $J=2.4\text{Hz}$), 3. 8.21 (1H, d, $J=2.4\text{Hz}$)
Ex. 2-82		8.23 (1H, d, $J=2.4\text{Hz}$), 8.20 (1H, d, $J=2.4\text{Hz}$), 7.15 (2H, d, $J=8.3\text{Hz}$), 7.10 (2H, d, $J=8.3\text{Hz}$), 5.33 (1H, m), 3.59-3.48 (2H, m), 3.42-3.31 (2H, m), 3.39 (3H, s), 2.27 (3H, s), 2.18-2.07 (2H, m), 1.96-1.83 (2H, m), 1.61-1.55 (2H, m), 1.48-1.42 (2H, m)
Ex. 2-83		8.23 (1H, d, $J=2.5\text{Hz}$), 8.20 (1H, d, $J=2.5\text{Hz}$), 7.20 (2H, d, $J=8.8\text{Hz}$), 6.91 (2H, d, $J=8.8\text{Hz}$), 5.34 (1H, m), 3.74 (3H, s), 3.61-3.51 (2H, m), 3.43 (3H, s), 3.42-3.32 (2H, m), 2.19-2.07 (2H, m), 1.96-1.82 (2H, m), 1.61-1.55 (2H, m), 1.47-1.41 (2H, m)
Ex. 2-84		(300MHz, DMSO-D6), 1.47-1.63 (4H, m), 3.26-4.55 (8H, m), 3.37 (3H, s), 4.49 (2H, s), 7.11-7.39 (5H, m), 7.59 (1H, dd, $J=8.4$, 2.2Hz), 7.78 (1H, d, $J=2.2\text{Hz}$), 8.01 (1H, d, $J=8.4\text{Hz}$), 11.8 (1H, brs)
Ex. 2-85		400MHz, DMSO-d6, 1.28-1.53 (4H, m), 3.05-3.16 (4H, m), 3.18-3.28 (4H, m), 3.24 (3H, s), 7.01-7.11 (3H, m), 7.18-7.23 (2H, m), 7.27-7.35 (3H, m), 7.41-7.47 (1H, m)
Ex. 2-86		400MHz, DMSO-d6, 1.47-1.68 (4H, m), 1.82-2.20 (4H, m), 3.28-3.39 (2H, m), 3.42 (3H, s), 3.62-3.79 (2H, m), 4.70-4.84 (1H, m), 7.18-7.43 (5H, m), 8.65 (2H, s)
Ex. 2-87		400MHz, DMSO-d6, 1.26-1.48 (4H, m), 2.57-2.67 (4H, m), 2.98-3.05 (4H, m), 3.19 (3H, s), 3.75 (2H, s), 6.98-7.06 (2H, m), 7.17-7.41 (4H, m), 7.46-7.51 (2H, m)
Ex. 2-88		(300MHz, DMSO-d6) 1.47 (2H, m), 1.74 (2H, m), 1.81-1.89 (2H, m), 1.99-2.11 (2H, m), 3.23-3.30 (3H, m), 3.40-3.48 (5H, m), 7.49 (1H, dd, $J=8.2$, 2.4Hz), 7.64 (1H, d, $J=1.8\text{Hz}$), 7.86 (1H, d, $J=8.5\text{Hz}$),

		8.21 (2H, dd, J=8.2, 2.0Hz)
Ex. 2-89		
Ex. 2-90		
Ex. 2-91		
Ex. 2-92		
Ex. 2-93		
Ex. 2-94		
Ex. 2-95		
Ex. 2-96		
Ex. 2-97		
Ex. 2-98		



Experimental Example: *in vitro* HSD1 (hydroxysteroid dehydrogenase 1) activity inhibitory action

The HSD1 inhibitory activity was examined by

5 quantitative determination by an SPA (scintillation proximity assay) system of the suppressive action on the conversion from cortisone to cortisol using human HSD1 (hereinafter recombinant HSD1) expressed using a baculo-virus system as an enzyme source. For the reaction, a reagent was added to a 96

10 well plate (96 well Opti-plates™-96 (Packard)) to the following final concentration and a volume of 100 μ l was reacted at room temperature for 90 min. The reaction solution used was 0.1 μ g/ml recombinant HSD1, 500 μ M NADPH, 16 nM 3 H cortisone (Amersham Biosciences, 1.78 Tbq/mol) dissolved in

15 0.1% BSA (Sigma)-containing PBS and the test drug was 2 μ l of a compound solution (dissolved in DMSO). After 90 min, the reaction was stopped by adding PBS (40 μ l, containing 0.1% BSA (Sigma)) containing 0.08 μ g of anti-cortisol mouse monoclonal antibody (East Coast Biologics), 365 μ g SPA PVT mouse antibody-

20 binding beads (Amersham Biosciences) and 175 μ M carbenoxolone (Sigma) to the reaction solution. After the completion of the reaction, the plate was incubated overnight at room temperature and the radioactivity was measured by Topcount (Packard). For control, the value (0% inhibition) of the well

25 containing 2 μ l of DMSO instead of the test drug was used, and for positive control, the value (100% inhibition) of the well containing carbenoxolone instead of the test drug at the final concentration of 50 μ M was used. The inhibition (%) of the test drug was calculated by ((value of control - value of test

drug)/(value of control - value of positive control)) x 100 (%). The IC₅₀ value was analyzed using a computer-based curve fitting soft. The obtained results are shown in the following Table.

5

Examples	hHSD1 IC ₅₀
Ex.1-1	+
Ex.1-2	++
Ex.1-4	+
Ex.1-5	++
Ex.1-6	+
Ex.1-7	+
Ex.1-8	++
Ex.1-10	+
Ex.1-11	+
Ex.1-12	+
Ex.1-13	++
Ex.1-14	++
Ex.1-15	++
Ex.1-16	+
Ex.1-18	++
Ex.1-19	++
Ex.1-20	++
Ex.1-21	++
Ex.1-22	++
Ex.1-23	++
Ex.1-24	++
Ex.1-25	++
Ex.1-26	++
Ex.1-27	+
Ex.1-28	++
Ex.1-29	++
Ex.1-30	++
Ex.1-31	++

Ex.1-32	++
Ex.1-33	+
Ex.1-34	++
Ex.1-35	++
Ex.1-36	++
Ex.1-38	++
Ex.1-39	++
Ex.1-40	+
Ex.1-41	+
Ex.1-42	+
Ex.1-43	+
Ex.1-44	+
Ex.1-45	+
Ex.1-46	+
Ex.1-47	++
Ex.1-48	+
Ex.1-49	++
Ex.1-50	++
Ex.1-51	++
Ex.1-52	++
Ex.1-53	++
Ex.1-54	++
Ex.1-55	++
Ex.1-56	++
Ex.1-57	++
Ex.1-58	++
Ex.1-59	+
Ex.1-60	++
Ex.1-61	+
Ex.1-62	++
Ex.1-63	++
Ex.1-64	+
Ex.1-65	++
Ex.1-66	++
Ex.1-67	++

Ex.1-68	++
Ex.1-69	++
Ex.1-70	++
Ex.1-71	++
Ex.1-72	+
Ex.1-73	++
Ex.1-74	+
Ex.1-75	++
Ex.1-76	++
Ex.1-77	+
Ex.1-78	+
Ex.1-79	+
Ex.1-80	+
Ex.1-81	+
Ex.1-82	++
Ex.1-83	+
Ex.1-84	+
Ex.1-85	+
Ex.1-87	+
Ex.1-88	+
Ex.1-89	++
Ex.1-90	++
Ex.1-91	++
Ex.1-92	++
Ex.1-93	++
Ex.1-94	+
Ex.1-95	++
Ex.1-96	++
Ex.1-97	+
Ex.1-98	+
Ex.1-99	+
Ex.1-100	++
Ex.1-101	++
Ex.1-102	++
Ex.1-103	++

Ex.1-104	+
Ex.1-105	++
Ex.1-106	++
Ex.1-107	++
Ex.1-108	++
Ex.1-109	++
Ex.1-110	++
Ex.1-111	+
Ex.1-112	++
Ex.1-113	++
Ex.1-114	++
Ex.1-115	++
Ex.1-116	++
Ex.1-117	++
Ex.1-118	++
Ex.1-119	++
Ex.1-120	++
Ex.1-121	++
Ex.1-122	++
Ex.1-123	++
Ex.1-124	+
Ex.1-125	++
Ex.1-126	+
Ex.1-127	++
Ex.1-128	++
Ex.1-129	++
Ex.1-130	+
Ex.1-131	++
Ex.1-132	++
Ex.1-134	++
Ex.2-1	++
Ex.2-2	+
Ex.2-4	+
Ex.2-5	+
Ex.2-6	++


Ex.2-7	+
Ex.2-8	+
Ex.2-9	+
Ex.2-10	+
Ex.2-11	+
Ex.2-12	+
Ex.2-13	+
Ex.2-14	++
Ex.2-15	++
Ex.2-16	++
Ex.2-17	+
Ex.2-18	+
Ex.2-19	+
Ex.2-20	++
Ex.2-21	++
Ex.2-22	+
Ex.2-23	+
Ex.2-24	++
Ex.2-25	++
Ex.2-26	+
Ex.2-27	+
Ex.2-28	++
Ex.2-29	+
Ex.2-30	++
Ex.2-31	++
Ex.2-32	++
Ex.2-33	+
Ex.2-34	+
Ex.2-35	++
Ex.2-36	++
Ex.2-37	+
Ex.2-38	++
Ex.2-39	++
Ex.2-40	+
Ex.2-41	+










Ex.2-42	+
Ex.2-43	+
Ex.2-44	+
Ex.2-45	+
Ex.2-46	+
Ex.2-47	+
Ex.2-48	++
Ex.2-49	++
Ex.2-50	+
Ex.2-51	++
Ex.2-52	++
Ex.2-53	++
Ex.2-54	+
Ex.2-55	+
Ex.2-56	+
Ex.2-57	+
Ex.2-58	++
Ex.2-59	++
Ex.2-60	++
Ex.2-61	++
Ex.2-62	+
Ex.2-63	+
Ex.2-64	+
Ex.2-65	++
Ex.2-66	+
Ex.2-67	++
Ex.2-68	++
Ex.2-69	+
Ex.2-70	++
Ex.2-71	+
Ex.2-72	+
Ex.2-73	++
Ex.2-74	+
Ex.2-75	++
Ex.2-76	++

Ex.2-77	+
Ex.2-78	++
Ex.2-79	++
Ex.2-80	++
Ex.2-81	++
Ex.2-82	+
Ex.2-83	+
Ex.2-84	+
Ex.2-85	++
Ex.2-86	+
Ex.2-87	+
Ex.2-88	+
Ex.2-89	+
Ex.2-90	+
Ex.2-91	++
Ex.2-92	++
Ex.2-93	++
Ex.2-94	++
Ex.2-95	++
Ex.2-96	++

In the above Table, "+" in the column of IC_{50} means $10nM \leq IC_{50} < 1,000nM$ and "++" in the column of IC_{50} means $IC_{50} < 10nM$.

5 In the same manner as in Example 1-1 or 2-1, and using other conventional methods as necessary, the triazole compounds shown in the following Table can be also produced.

Compound No.	Molecular Structure	R
1-1001		

1-1002		
1-1003		
1-1004		
1-1005		
1-1006		
1-1007		
1-1008		
1-1009		
1-1010		

1-1011		
1-1012		
1-1013		
1-1014		
1-1015		
1-1016		
1-1017		
1-1018		
1-1019		

1-1020		
1-1021		
1-1022		
1-1023		
1-1024		
1-1025		
1-1026		

1-1027		
1-1028		
1-1029		
1-1030		
1-1031		
1-1032		
1-1033		
1-1034		
2-1001		

2-1002		
2-1003		H
2-1004		-CH ₃
2-1005		*-CH ₂ CO ₂ H
2-1006		*-CH ₂ CO ₂ CH ₃
2-1007		*-CH ₂ CONH ₂
2-1008		*-CH ₂ CH(OH)CH ₃
2-1009		H


2-1010		-CH ₃
2-1011		*-CH ₂ CO ₂ H
2-1012		*-CH ₂ CO ₂ CH ₃
2-1013		*-CH ₂ CONH ₂
2-1014		*-CH ₂ OH
2-1015		H
2-1016		-CH ₃
2-1017		*-CH ₂ CO ₂ H
2-1018		*-CH ₂ CO ₂ CH ₃

2-1019		
2-1020		

As mentioned above, the triazole compound of the present invention has superior HSD1 inhibitory activity and is useful as an HSD1 inhibitor, a therapeutic drug of diabetes or
⁵ a therapeutic drug of obesity.

WHAT IS CLAIMED IS:

1. A triazole compound represented by the following formula:



5

wherein

R¹ is an alkyl group or a cycloalkyl group

wherein the alkyl group and the cycloalkyl group are
optionally substituted by 1 to 5 substituents each
10 independently selected from a halogen atom, -CF₃, -OH,
-NH₂, an alkoxy group, a cycloalkyl group, an alkenyl
group, -COOH, -CO-O-alkyl, -CO-N(R⁷)(R⁸), -N(R⁷)-CO-R⁸, an
aryl group and a heteroaryl group

wherein R⁷ and R⁸ are each independently a hydrogen
15 atom or an alkyl group, and the aryl group and the
heteroaryl group are optionally substituted by 1 to 3
substituents each independently selected from a
halogen atom, a haloalkyl group, an alkyl group,
- (CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a
20 cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl
group and a heteroaryl group

wherein n is 0-3, R⁹ and R¹⁰ are each independently
a hydrogen atom, an alkyl group or -CO-alkyl, and
R¹¹ is -OH, an alkoxy group, an alkyl group or
25 -N(R¹²)(R¹³) wherein R¹² and R¹³ are each
independently a hydrogen atom or an alkyl group;

Y is a cycloalkyl group or a heterocycloalkyl group
wherein the cycloalkyl group and the heterocycloalkyl
group are optionally substituted by 1 to 3

substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above);

5 Ar¹ is an aryl group or a heteroaryl group;

R² and R³

10 are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group or a heteroaryl group

15 wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above);


20 Z is -(CH(R¹⁴))_p- , -(CH(R¹⁴))_p-N(R¹⁶)-(CH(R¹⁵))_q- or



25 wherein Y₁ is a cycloalkyl group or a heterocycloalkyl group

30 wherein the cycloalkyl group and the heterocycloalkyl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy


group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above),
 5 p is 0-3, q is 0-3, R¹⁴ and R¹⁵ are each independently a hydrogen atom, a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and
 10 R¹⁶ is a hydrogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -(CH₂)_n-CO-R¹¹, a cycloalkyl group, an alkenyl group, an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and
 15 R¹⁶ is a hydrogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -(CH₂)_n-CO-R¹¹, a cycloalkyl group, an alkenyl group, an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and
 20 R¹⁶ is a hydrogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -(CH₂)_n-CO-R¹¹, a cycloalkyl group, an alkenyl group, an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰), -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and
 25 R¹⁶ is a hydrogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -(CH₂)_n-CO-R¹¹, a cycloalkyl group, an alkenyl group, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above);
 Ar² is an aryl group, a heteroaryl group or



wherein X_1 is $-(CH_2)_t-$ wherein t is 0-2, V_1 is $=CH-$ or $=N-$, and W_1 is $-C(R^{17})(R^{18})-$, $-O-$, $-S-$, $-SO_2-$, $-SO-$, $-CO-$ or $-N(R^{19})-$

5 wherein R^{17} and R^{18} are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, $-(CH_2)_r-OH$, $-CO-R^{20}$, $-N(R^{21})(R^{22})$ or $-L_1-Ar^3$ wherein r is 0-3, R^{20} is $-OH$, an alkoxy group, an alkoxyalkyl group or $-N(R^{23})(R^{24})$

10 wherein R^{23} and R^{24} are each independently a hydrogen atom, an alkyl group, $-(CH_2)_s-OH$, an alkoxyalkyl group, or in combination form



wherein s is 0-3, X_2 is $-O-$, $-(CH_2)_t-$ or $-N(R^{25})-$

15 wherein t is as defined above and R^{25} is a hydrogen atom, $-CO-R^{26}$, $-SO_2-R^{26}$ or $-(CH_2)_u-Ar^4$

wherein R^{26} is an alkyl group, an alkoxy group, $-NH-alkyl$ or $-N(-alkyl)_2$, u is 0-3, and Ar^4 is an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, $-(CH_2)_n-OH$, $-N(R^9)(R^{10})$, $-CN$, $-NO_2$, an alkoxy group, a cycloalkyl group, an alkenyl group, $-CO-R^{11}$, an aryl group and a heteroaryl group (n , R^9 , R^{10} and R^{11} are as defined above),

20 L_1 is $-(CH_2)_v-$, $-O-$ or $-CO-$

25 wherein v is 0-3, and

30 Ar^3 is an aryl group or a heteroaryl group wherein the aryl group and the heteroaryl group are optionally

substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, $-(CH_2)_n-OH$, $-N(R^9)(R^{10})$, $-CN$, $-NO_2$, an alkoxy group, a cycloalkyl group, an alkenyl group, $-CO-R^{11}$, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and
5 R²¹ and R²² are each independently a hydrogen atom, an alkyl group, -CO-alkyl, -CO-O-alkyl or -L₁-Ar³ (L₁ and Ar³ are as defined above), and

10 R¹⁹ is a hydrogen atom, -CO-R²⁶, -SO₂-R²⁶ or $-(CH_2)_u-Ar^4$ (R²⁶, u and Ar⁴ are as defined above); and

R⁴ and R⁵

15 are each independently a hydrogen atom, a halogen atom, -OH, -NO₂, -CN, an alkyl group, an alkoxy group, -CO-R²⁷, -SO₂-R²⁷, -CO-N(R²⁸)(R²⁹) or -N(R³⁰)(R³¹)

20 wherein the alkyl group and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, -CF₃, -OH, an alkoxy group, a haloalkoxy group, $-N(R^9)(R^{10})$, -CN, -NO₂, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (R⁹, R¹⁰ and R¹¹ are as defined above),


25 wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, $-(CH_2)_n-OH$, $-N(R^9)(R^{10})$, -CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above)

30 R²⁷ is -OH, an alkoxy group, an alkyl group, -NH₂, -NH-alkyl or -N(-alkyl)₂,

R^{28} and R^{29} are each independently a hydrogen atom, an alkyl group or $-(CH_2)_w-R^{32}$,


wherein w is 0-3 and R^{32} is $-\text{OH}$, $-\text{CF}_3$, an alkoxy group, $-\text{CONH}_2$ or $-\text{N}(R^{33})(R^{34})$

5 wherein R^{33} and R^{34} are each independently a hydrogen atom, an alkyl group, $-\text{CO-alkyl}$, or in combination form



(X_2 is as defined above)

or R^{28} and R^{29} in combination form



10 wherein X_3 is $-\text{CO-}$, $-\text{CH}_2-$ or $-\text{CH}_2-\text{CH}_2-$, X_4 is

- O- , $-(\text{CH}_2)_t-$, $-\text{N}(R^{25})-$ or

wherein Y_2 is cycloalkyl or heterocycloalkyl and t and R^{25} are as defined above, and R^{35} and R^{36} are each independently a hydrogen atom, a halogen atom, an alkyl group optionally substituted by $-\text{OH}$, $-\text{OH}_2$, $-\text{CN}$, $-\text{NO}_2$, an alkoxy group, a cycloalkyl group, an alkenyl group, $-\text{CO-R}^{37}$, $-\text{N}(R^{38})(R^{39})$

20 wherein R^{37} is $-\text{OH}$, an alkoxy group, $-\text{NH}_2$,

- NH-alkyl , $-\text{N}(-\text{alkyl})_2$ or (X_2 is as defined above)

25 wherein the alkyl group in $-\text{NH-alkyl}$ and $-\text{N}(-\text{alkyl})_2$ and the alkoxy group are optionally substituted by 1 to 5 substituents each independently selected from a halogen atom, $-\text{CF}_3$, $-\text{OH}$,


an alkoxy group, a haloalkoxy group, -N(R⁹)(R¹⁰), -CN, -NO₂, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (R⁹, R¹⁰ and R¹¹ are as defined above),

wherein the aryl group and the heteroaryl group are optionally substituted by 1 to 3 substituents each independently selected from a halogen atom, a haloalkyl group, an alkyl group, -(CH₂)_n-OH, -N(R⁹)(R¹⁰),

-CN, -NO₂, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R¹¹, an aryl group and a heteroaryl group (n, R⁹, R¹⁰ and R¹¹ are as defined above), and

R³⁸ and R³⁹ are each independently a hydrogen atom, an alkyl group, -CO-alkyl or -CO-O-alkyl, and

R³⁰ and R³¹ are each independently a hydrogen atom, an alkyl group optionally substituted by -OH, -SO₂-




R⁴⁰, -(CH₂)_x-CO-R⁴¹ or

wherein x is 0-3, R⁴⁰ is an alkyl group or -NH₂, R⁴¹ is a hydrogen atom, an alkyl group optionally substituted by -OH, -OH, an alkoxy group, an alkoxyalkyl group or -(CH₂)_s-N(R⁴²)(R⁴³)

wherein s is as defined above and R⁴² and R⁴³ are each independently a hydrogen atom, an alkyl group, -OH, an alkoxy group, or in

combination form



(X₃, X₄, R³⁵ and R³⁶ are as defined

above),

V₂ is =CH- or =N- and W₂ is -C(R⁴⁴)(R⁴⁵)-, -O- or
5 -N(R⁴⁶)-

wherein R⁴⁴ and R⁴⁵ are each independently a hydrogen atom, an alkyl group, an alkoxy group, a haloalkyl group, -(CH₂)_r-OH, -CO-R⁴⁷ or -N(R⁴⁸)(R⁴⁹)


10 wherein r is as defined above, R⁴⁷ is -OH, an alkoxy group, an alkoxyalkyl group, -N(R⁵⁰)(R⁵¹)

15 wherein R⁵⁰ and R⁵¹ are each independently a hydrogen atom, an alkyl group, -(CH₂)_s-OH (s is as defined above) or an alkoxyalkyl group, and

20 R⁴⁸ and R⁴⁹ are each independently a hydrogen atom, an alkyl group, -CO-alkyl or -CO-O-alkyl, and

R⁴⁶ is a hydrogen atom, -CO-R⁵² or -SO₂-R⁵² wherein R⁵² is an alkyl group, an alkoxy group, -NH-alkyl or -N(-alkyl)₂ or

25 R³⁰ and R³¹ in combination form



(X₃, X₄, R³⁵ and R³⁶ are as defined above),

or

R⁴ and R⁵ in combination may form -O-alkylene-O-, a prodrug thereof or a pharmaceutically acceptable salt

thereof.

2. The triazole compound of claim 1, wherein Z is $-(CH(R^{14}))_p-$ and p is 0, a prodrug thereof or a pharmaceutically acceptable salt thereof.

3. The triazole compound of claim 2, wherein Y is a C_{3-8} cycloalkyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

10

4. The triazole compound of claim 3, wherein Ar^1 is a phenyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

15 5. The triazole compound of claim 4, wherein R^2 and R^3 are each independently a halogen atom or a hydrogen atom, a prodrug thereof or a pharmaceutically acceptable salt thereof.

20 6. A pharmaceutical composition comprising the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

25 7. An HSD1 (11beta-hydroxysteroid dehydrogenase 1) inhibitor comprising the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

30 8. A therapeutic or prophylactic drug of diabetes, which comprises the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

9. A therapeutic or prophylactic drug of obesity, which comprises the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

10. A therapeutic or prophylactic drug of metabolic syndrome, which comprises the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

11. A method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

12. A method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

13. A method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of the triazole compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

14. The method of claim 11, wherein a different therapeutic drug of diabetes is used in combination.

15. The method of claim 14, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a

sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an α -glucosidase inhibitor and an insulin sensitizer.

5 16. The method of claim 15, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopypamide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin 10 hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

17. The method of claim 12, wherein a different therapeutic drug of diabetes is used in combination.

15 18. The method of claim 17, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a 20 biguanide, an α -glucosidase inhibitor and an insulin sensitizer.

19. The method of claim 18, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected 25 from the group consisting of insulin, glibenclamide, tolbutamide, glyclopypamide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

30 20. The method of claim 13, wherein a different therapeutic drug of diabetes is used in combination.

21. The method of claim 20, wherein the different therapeutic drug of diabetes is one or more pharmaceutical agents selected from the group consisting of an insulin preparation, a 5 sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an α -glucosidase inhibitor and an insulin sensitizer.

22. The method of claim 21, wherein the different therapeutic 10 drug of diabetes is one or more pharmaceutical agents selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopypamide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformine hydrochloride, voglibose, acarbose 15 and pioglitazone hydrochloride.

23. The method of claim 11, wherein a different therapeutic drug of obesity is used in combination.

20 24. The method of claim 23, wherein the different therapeutic drug of obesity is Mazindol.

25. The method of claim 12, wherein a different therapeutic drug of obesity is used in combination.

26. The method of claim 25, wherein the different therapeutic drug of obesity is Mazindol.

27. The method of claim 13, wherein a different therapeutic 30 drug of obesity is used in combination.


28. The method of claim 27, wherein the different therapeutic

drug of obesity is Mazindol.

ABSTRACT OF THE DISCLOSURE

The present invention provides a triazole compound of the following formula:

5



a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound has superior HSD1 inhibitory activity, and is useful as an HSD1 inhibitor,
10 a therapeutic drug of diabetes or a therapeutic drug of obesity or a therapeutic drug of metabolic syndrome.